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                                            Abstract
Background and aims. Given that the pathogenesis of type 1 and 2 diabetes are mark-
edly different, it is possible that patients with type 2 diabetes should not be treated with insu-
lin following the principles used for treatment of type 1 diabetes. The present studies were
undertaken to define 1) the optimal insulin treatment regimen for type 2 diabetic patients with
secondary failure to oral anti-diabetic drugs (OAD), 2) causes of inter-individual variation in
insulin requirements in type 2 diabetic patients and 3) how improvement of glycemic control
by insulin therapy influences markers of endothelial activation as measured by serum con-
centrations of the soluble adhesion molecules sE-selectin and vascular cell adhesion molecule
(sVCAM-1).
Subjects, study designs and methods. 153 poorly controlled type 2 diabetic patients who
were treated with maximal doses of sulfonylurea  alone or in combination with metformin
were randomized to treatment for 3 months with either continued OAD and NPH insulin in
the evening or continued OAD and NPH insulin in the morning, a 2 insulin injection regimen
without OAD or a multiple insulin injection regimen without OAD. The goal was to achieve
similar glycemic control with all insulin regimens and to compare effects of various regimens
on insulin requirements, body weight, serum lipids and lipoproteins and episodes of hypogly-
cemia (study I). Study II was designed to determine what bedtime NPH insulin should be
combined with, a sulfonylurea, metformin, both drugs or another injection of NPH insulin.
Ninety-six   type 2 diabetic patients who were treated with a maximal dose of sulfonylurea,
were randomized to treatment for one year with bedtime NPH insulin and glibenclamide, or
bedtime NPH insulin and metformin, or bedtime NPH insulin and glibenclamide and metfor-
min, or bedtime NPH insulin and morning NPH insulin. The patients were taught to self ad-
just their insulin doses. In study III, 20 type 2 diabetic patients with stable glucose control and
insulin dose, who were treated with combination therapy with bedtime NPH insulin and met-
formin for at least 1 year were studied. In each subject, the following measurements were per-
formed: 1) measurement of action of intravenous insulin on endogenous glucose production
(EGO) and utilization, (euglycemic insulin clamp combined with [3-3H]glucose)  2) meas-
urement of absorption (increase in free insulin and total insulin over 8 h after subcutaneous
dose of regular insulin) and action of subcutaneous insulin (glucose infusion rate required to
maintain euglycemia and suppress  FFA) and 3) measurement of liver (proton spectroscopy)
and intra-abdominal (magnetic resonance imaging) fat content and in addition, body weight,
body composition, and the thickness of subcutaneous abdominal (ultrasound) fat were deter-
mined. In study IV, 81 type 2 diabetic patients, who participated in study II and 41 normal
subjects  were studied. In these groups, concentrations of serum sE-selectin and sVCAM-1
concentrations were determined. In the type 2 diabetic patients, the measurements were re-
peated at 3 and 12 months.
Results. Study I: The mean insulin doses of NPH insulin in the two groups receiving an
OAD and NPH insulin were similar and 60 %  lower than in the 2-injection or multiple injec-
tion group. The total doses of insulin were comparable in the 2- and multiple insulin injection
groups. HbA1c concentrations decreased from approximately 8 to 10 % in all the insulin-
treatment groups. All groups receiving insulin therapy gained weight. The smallest increment
in body weight occurred in the OAD and evening NPH insulin group and the largest in the
multiple-injection group (p < 0.05). The frequency of hypoglycemia was similar in all insulin
treated groups. The concentration of serum VLDL triglycerides decreased by 13 to 28 % in
the insulin treatment groups with no differences between the groups who used insulin. The
concentrations of total, LDL, and HDL cholesterol remained unchanged. Study II: Patients
receiving bedtime insulin and metformin showed a progressive decrease in HbA1c concentra-
tions over time. At 12 months, HbA1c  values in this group averaged 7.2 % ± 0,2 %; which
differed significantly from that  in the other groups. Patients receiving bedtime insulin and
metformin did not gain weight unlike the other groups. The frequency of hypoglycemic epi-
sodes in patients receiving bedtime insulin and metformin was significantly lower (p < 0.05)
than that in patients receiving bedtime and morning insulin. Hypoglycemia limited adequate
titration of the insulin dose in the group using NPH insulin and glibenclamide. Serum triglyc-
eride concentrations decreased similarly in all groups. Study III: The amount of  insulin ab-
sorbed was significantly correlated with glucose infusion rate required to maintain euglyce-
mia ( r = 0.74, p < 0.001) and  suppression of  FFA ( r = -0.63, p < 0.005). On the other hand,
the actions of intravenous and subcutaneous insulin were so closely correlated that the contri-
bution of variation in insulin absorption to interindividual variation in insulin action was
maximally 30 %. Of the relationships of measures of overall  adiposity and fat distribution,
the % liver fat was the best correlate of the %  suppression of  EGO by intravenous insulin. In
multiple linear regression, 61.3% of variation in the daily insulin dose (units per day) could be
explained by variation in the ability of subcutaneous insulin to suppress FFA (p < 0.001) and
by insulin antibodies (p = 0.05). Of all measures of adiposity, the % liver fat was the parame-
ter best correlated with the insulin dose. Study IV. Serum sE-selectin concentrations were 71
% higher in the type 2 diabetic patients than in the normal subjects before insulin therapy.
During insulin therapy, sE-selectin concentrations decreased significantly compared to 0
month but the concentration at 12 months was still 55 % higher than in the normal subjects.
Serum sVCAM-1 decreased transiently during the first 3 months and then increased back to
baseline  by 12 months. The change in HbA1c, both in diabetic men and women, was signifi-
cantly correlated with the change in sE-selectin concentrations.
Conclusions.  In poorly controlled type 2 diabetic patients receiving OAD therapy, the
addition of NPH insulin in the evening improves glycemic control in a similar manner as a
two-insulin-injection therapy regimen and multiple-insulin-therapy regimen, but induces less
weight gain and hyperinsulinemia.  Combination therapy with bedtime insulin and metformin
prevents weight gain and seems superior to other bedtime insulin regimens with respect to
improvement in glycemic control and frequency of hypoglycemia. Self-adjustment of the in-
sulin dose is critically important to achieve glycemic targets. The major reason for inter-
individual variation in insulin requirements in type 2 diabetes is variation in insulin action.
Variation in hepatic fat content may influence insulin requirements via an effect on the sensi-
tivity of EGO to insulin. Improvement in glycemic control by insulin alone or insulin com-
bined with either glibenclamide, metformin, or both agents induces a sustained decrease in
sE-selectin, the magnitude of which seems to be dependent on the degree of improvement in
glycemic control. Serum sE-selectin might provide a marker of effects of treatment of chronic
hyperglycemia on endothelial activation.
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1. INTRODUCTION
It has been estimated that the global prevalence of type 2 diabetes will rise from
about 160 million in the year 2000 to approximately 215 million in 2010 (29). The
mortality from cardiovascular disease (CVD) and the incidence of non-fatal coro-
nary heart disease (CHD) events is 2 to 4 times higher in patients with type 2 dia-
betes than in normal subjects and is the major cause of death of these patients
(243,275,485). The overall objective of treatment of type 2 diabetes is to prevent
acute and chronic complications while maintaining a high quality of life.
We know that the typical type 2 diabetic patient is obese and insulin resistant and
has by definition residual insulin secretion (5,295,405). This knowledge raises the
possibility that patients with type 2 diabetes may perhaps not benefit from the same
type of insulin therapy than patients with type 1 diabetes, who are usually lean and
often have hypoglycemic problems during insulin therapy. Until 1989, when the
FINMIS (I) study was started, little was, however, known of whether and how pa-
tients with type 2 diabetes should be treated with insulin once oral antidiabetic
drugs (OAD) no longer were able to maintain satisfactory glycemic control. Pa-
tients with type 2 diabetes were frequently admitted to the hospital, put on a diet
meant for ‘insulin-treated diabetic patients’ which included 3 main meals and often
even 3 snacks. The concept that C-peptide is a better marker of insulin resistance
than secretion in type 2 diabetic patients was not commonly known. This some-
times resulted in abandoning insulin therapy in obese patients because "normal" or
"elevated" C-peptide concentration was considered to imply sufficient insulin se-
cretion despite simultaneous hyperglycemia. In the literature, there were very few
randomized comparisons of different insulin treatment regimens in patients with
type 2 diabetes. For example, in a meta-analysis published in 1991 (382), only 8
concurrent and 14 cross-over trials were identified with a mean of 11 and 14 pa-
tients per group. In these studies, glycemic control was concluded to be, on the av-
erage, better in patients treated with insulin and sulfonylureas than with insulin
alone, and the dose of exogenous insulin was lower in those using insulin combina-
tion therapy compared to patients using insulin alone. These data documented that
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oral agents do work even in poorly controlled patients with type 2 diabetes. On the
other hand, these studies taught us little regarding the possible superiority of insulin
combination therapy compared to insulin alone. Given that sulfonylureas still work
even in advanced disease, their apparent superiority might simply have been ex-
plained by failure to decrease exogenous insulin doses sufficiently to match the
potency of the sulfonylurea (531). Another issue that had not been tested was
whether administration of insulin at bedtime might prevent weight gain compared
to administration of the same dose of insulin in the morning or whether use of mul-
tiple insulin injections merely results in weight gain and no benefits with respect to
glycemic control compared to simpler regimens. Another open question, still in
1994 when the FINFAT (II) study was started, was whether use of metformin might
counteract weight gain which is inevitable when glycemic control is improved.
There were also no data on what determines insulin requirements in patients with
type 2 diabetes. This would seem of interest as type 2 diabetic patients vary greatly
with respect to body weight and composition and insulin sensitivity. Finally, very
little attention has been paid to effects of insulin therapy on parameters other than
glycemic control and lipids and lipoproteins. These include effects of insulin ther-
apy on various measures of vascular function such as on endothelial function, in-
flammatory markers and measures of coagulation and fibrinolysis.
The present studies were undertaken to define the optimal insulin treatment regi-
men for patients with type 2 diabetes. We also wished to search for causes of inter-
individual variation in insulin requirements in type 2 diabetes and were interested to
determine effects of insulin therapy on markers of endothelial function.
16
2. REVIEW OF THE LITERATURE
2.1 PATHOGENESIS OF TYPE 2 DIABETES
2.1.1. Definition of type 2 diabetes
Diagnostic criteria
The diagnostic criteria of diabetes are similar regardless of the etiology of hyper-
glycemia. The first generally accepted criteria were published in 1979 by the Na-
tional Diabetes Data Group classification (3). The recommendations of the National
Diabetes Data Group were endorsed by the World Health Organisation (WHO) Ex-
pert Committee on Diabetes in 1980 and the World Organisation Study Group on
Diabetes Mellitus in 1985 (5). These diagnostic criteria have recently been re-
examined. The American Diabetes Association published new criteria in 1997 and
the experts of WHO published highly similar criteria in 1998 (468) (Table 1).
The new aspects of these WHO criteria were: 1) the concentration of fasting plasma
glucose, measured from venous blood, which establishes the diagnosis of diabetes
is 7.1 mmol/l instead of 7.8 mmol/l, 2) a new category of altered glucose homeosta-
sis called impaired plasma fasting glucose (IFG) was introduced, and defined as a
fasting plasma glucose concentration between 6.1 and 7.0 mmol/l, 3) the terms in-
sulin-dependent and non-insulin-dependent were discarded and replaced by the
terms type 1 and type 2 diabetes.
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Table 1. The new WHO diagnostic criteria for diabetes and other hy-
perglycaemic states (468). The oral glucose load used to determine oral
glucose tolerance is 75g or 1.75g/kg for children. The diagnostic criteria
are  the same for adults and children.
Glucose concentration in mmol/l (mg/dl)
               Plasma                                   Whole blood
  Venous            Capillary             Venous          Capillary
Diabetes mellitus
Fasting value
or
2 h after 75 g
glucose load
≥ 7.0 (126)
≥ 11.1 (200)
> 7.0 (126)
≥ 12.2 (220)
≥ 6.1 (110)
≥ 10.0 (180)
≥ 6.1 (110)
≥ 11.1 (200)
IGT
Fasting value
(if measured)
and
2 h after 75 g
glucose load
< 7.0 (126)
7.8-11.0
(140-199)
< 7.0 (126)
8.9-12.1
(160-219)
< 6.1 (110)
6.7-9.9
(120-179)
< 6.1 (110)
7.8-11.0
(140-199)
IFG
Fasting value
and
(if measured)
2 h after 75 g
glucose load
≥ 6.1 (110)
and
< 7.0 (126)
< 7.8 (140)
≥ 6.1 (110)
and
< 7.0 (126)
< 8.9 (160)
≥ 5.6 (100)
and
< 6.1 (110)
< 6.7 (120)
≥ 5.6 (100)
and
< 6.1 (110)
< 7.8 (140)
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Etiologic types and stages
The etiological types and stages of disorders of glycemia are described in Fig. 1.
Fig. 1. Disorders of glycemia: etiologic types and stages. * Even
after presenting in ketoacidosis, these patients can briefly return
to normoglycemia without requiring continuous insulin therapy
( i.e., "honeymoon" remission). ** In rare instances, patients in
these categories (e.g. type 1 diabetes presenting in pregnancy)
may require insulin for survival.
Adapted from Report of the Expert Committee on the Diagnosis
and Classification of Diabetes Mellitus (468)
Type 1 diabetes is characterized by beta-cell destruction usually via autoimmune
mechanisms. The phenotype features of type 1 diabetes are early age at diagnosis,
often but not always acute severe insulin deficiency accompanied by symptoms of
hyperglycemia, ketoacidosis and subnormal body weight. GAD-antibodies can be
detected in 65 to 90% of patients at diagnosis (291,390,427). Complete insulin de-
ficiency usually develops during the few first years of the disease (34,434).
Type 2 diabetes is characterized by a combination of defects in insulin secretion
and action (117,249,490). Diagnosis is usually made in adults, although the average
age of onset is continuously decreasing perhaps as a consequence of increasing
obesity in teenagers and children (18,139). At least 80 % of type 2 diabetes patients
are overweight. Although the majority of type 2 diabetic patients are insulin resis-
tant and obese, a subset is non-obese, relatively insulin-sensitive and insulin-
deficient (5).
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A subgroup of patients initially classified as having type 2 diabetes have a slowly
evolving autoimmune type of diabetes, called latent autoimmune diabetes in adults
(LADA) (472). The presence of autoantibodies, either islet-cell autoantibodies
(ICA) and/or GAD- antibodies, is a marker for insulin dependency in patients with
type 2 diabetes (178,471,474). At diagnosis, patients with LADA usually have
clinical features of type 2 diabetes, but in such patients progressive autoimmune de-
struction of beta-cells occurs and may lead to absolute insulin deficiency and need
for insulin treatment within few years (470,546). In unselected patients clinically
classified as having at least initially type 2 diabetes approximately 10% have GAD-
antibodies (355,474). These patients should, however, be classified as having type 1
diabetes according to the new classification criteria (17).
The genetics of type 2 diabetes in its most common type encountered in clinical
practice are complex (329). It is clear that there is no single major gene of over-
whelming importance in this type 2 diabetes (nothing akin to HLA in type 1). How-
ever, several genomic regions (e.g. on chromosomes 1, 7, 11 and 20) are showing
interesting replications across datasets and thus represent foci for detailed explora-
tion (329). Also, lifestyle-related factors such as physical activity levels and diet
are, next to age, the most important determinants of the penetrance of a given set of
diabetes-susceptibility genotypes. Although type 2 diabetes is generally a polygenic
disorder (329) there are some rare forms such as maturity onset diabetes in young
(MODY), which are monogenic autosomal dominantly inherited subtypes of type 2
diabetes. Mutations in five genes are currently known to cause MODY. These
genes encode hepatocyte nuclear factor-4 alpha (MODY 1), glucokinase (MODY
2), hepatocyte nuclear factor-1 alpha (MODY 3), insulin promotor factor-1 (MODY
4), and hepatocyte nuclear factor-1 beta (MODY 5). The genes cause several types
of abnormalities in insulin secretion. Patients with MODY can usually be treated
with diet and OAD and do not usually require long-term insulin therapy for sur-
vival, although no systematic comparison between different treatment regimens has
been performed (512).
Abnormalities in insulin action  and secretion as causes of type 2 diabetes
The pathogenesis of abnormal glucose metabolism in type 2 diabetes involves ab-
normalities in insulin secretion and insulin action. The sequence in which these ab-
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normalities develop and their relative contribution to the deterioration in glucose
tolerance and the progression from normal glucose tolerance (NGT) to impaired
glucose tolerance (IGT) and ultimately to type 2 diabetes is somewhat controver-
sial. Current understanding of the pathogenesis of type 2 diabetes is based on a
large number of cross-sectional (294,359,385,386) and prospective studies
(78,79,197,294,295,324,500). Also an overview of the pathogenesis of type 2 dia-
betes has been given in review articles (114,143).
In prospective studies, in which non-diabetic individuals have been metabolically
characterized, while still non-diabetic, and then followed for several years to de-
termine who develops diabetes, have helped to identify metabolic abnormalities
that predispose to diabetes. Lillioja S et al. (294,295) have shown that both a low
early insulin response and impaired insulin action predict diabetes in Pima Indians.
In Pima Indians (504), transition from NGT to IGT  is also associated with an in-
crease in body weight, a decline in insulin-stimulated glucose disposal and a de-
cline in the acute insulin secretory responce (AIR) to intravenous glucose. Progres-
sion from IGT to diabetes was accompanied by further increase in body weight, a
decrease in insulin-stimulated glucose disposal and the AIR and an increase in basal
endogenous glucose output (EGO). It has also been shown in other populations that
insulin resistance  predicts the development of type 2 diabetes (324,499).
Regarding the risk factors predisposing to type 2 diabetes, obesity is perhaps the
most important one (79,261,362,506). The US National Commission on Diabetes
reported that the risk of developing type 2 diabetes was about 2-fold increased in
mildly obese, 5-fold in moderately obese and 10-fold in severely obese people (2).
The relative risk imposed by obesity was highest among young people (20-45
years), whose risk was 3.8 times that of their non-overweight compatriots (489).
Weight gain, in addition to body mass index kg/m2  (BMI), is also a strong risk
factor for diabetes (76,89,137), as is the duration of obesity (136). The risk of type
2 diabetes increases not only as a function of overall obesity, but also with increas-
ing abdominal obesity, although there is increasing evidence that this applies more
to some population than the others (132,363). People with upper body obesity are
far more likely to develop type 2 diabetes than those with lower body obesity
(55,72,132,199).
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Lack of physical activity is another and perhaps the second most important risk
factor for the development of type 2 diabetes. The British Regional Heart Study
found that men who habitually were engaged in moderate levels of physical activity
had a substantially reduced risk of diabetes compared with physically inactive men,
even after adjustment for age, BMI and other risk factors (380). Physical training
enhances insulin sensitivity (121), which could be a major mechanism, via which
physical training prevents from diabetes.  Tuomilehto et al. have recently shown, in
their study addressing prevention of type 2 diabetes mellitus by changes in lifestyle
(diet and exercise) among subjects with IGT, that the cumulative incidence of dia-
betes after four years was 11 % in the intervention group and 23 % in the control
group. The risk of diabetes was reduced by 58 % (p < 0.001) in the intervention
group. The reduction in the incidence of diabetes was directly associated with
changes in lifestyle (473).
 2.1.2 Regulation of fasting and postprandial glucose concentrations
What determines the fasting plasma glucose concentration?
The liver is the most important source of glucose after an overnight fast (368). It is
responsible for the majority of  postabsorptive glucose release, the rest being of re-
nal origin. Glucose is produced every minute at a rate of approximately 11-12
µmol/kg of body weight (111). The brain is the major organ disposing glucose and
accounts for ~50 - 60 % of total glucose disposal (221). The splanchnic bed, eryth-
rocytes, and other parenchymal organs account for ~20 - 25 % of total glucose dis-
posal (119). Some  10 - 20 % is disposed of by skeletal muscles and 1-5 % by adi-
pose tissue (120) . Only ~10 - 20 % of whole body glucose disposal is insulin de-
pendent in the postabsorptive state (120). Thus only a small component of overall
glucose disposal will be affected by conditions of insulin resistance and/or defi-
ciency. On the other hand, glucose production is extremely sensitive to insulin (68).
Glucose production is the sum of glucose produced via glycogenolysis and gluco-
neogenesis (GLN). Approximately 20 % of glucose production can be attributed to
GLN, if calculated based on the extraction of  gluconeogenic precursors by the
splanchnic bed in non-diabetic subjects (498). When measured using [2-14
C]acetate, GLN accounts for ~30 % of EGO after an overnight fast (102). With this
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method, GLN increases 2-fold in subjects fasted for 2.5 days and then accounts for
> 97 % of overall glucose production which now is of both hepatic and renal origin.
When measured with [13 C] NMR imaging after 23 hours of fasting, GLN accounts
for as much as 70 % of overall glucose production in normal subjects  (424).
Regulation of the fasting glucose concentrations in type 2 diabetes
Several studies have shown that in patients with type 2 diabetes glucose production
is increased in the postabsorptive state and directly correlated with the fasting
plasma glucose concentration (68,117,411). Consoli et al.(103) and Magnusson et
al.(311) have shown that the rate of glycogenolysis is unaltered in type 2 diabetes
while  GLN is increased and the rate of GLN in type 2 diabetes is significantly cor-
related with the fasting plasma glucose concentration. Using NMR techniques
Magnusson et al.(311) have shown that hepatic glycogenolysis is even reduced in
patients with type 2 diabetes. These results provide strong evidence that increased
GLN is the main cause for increased EGO and fasting hyperglycemia in type 2 dia-
betes. Inhibition of GLN is not, however, sufficient to decrease fasting plasma glu-
cose concentrations in patients with type 2 diabetes, unless glygocenolysis is also
inhibited (395).
The mass-action effect of glucose. The rate of glucose uptake in muscle is influ-
enced not only by insulin but also by the ambient glucose concentration. The ability
of glucose to increase its own disposal is known as the mass-action effect of glu-
cose (530). The ability of glucose per se to increase glucose uptake is dependent on
the insulin concentration. The higher the insulin stimulated rate of glucose uptake,
the greater the ability of glucose to increase glucose uptake (540). It has been
shown that hyperglycemia in human diabetes increases glucose uptake in skeletal
muscle both in vivo (27,150) and in vitro (545). The mechanism does not involve
activation of PI 3-kinase, which is critical for normal action of insulin on glucose
uptake (545). This implies that hyperglycemia induced glucose uptake is not neces-
sarily impaired in insulin resistant individuals. However, in in vivo studies of pa-
tients with type 2 diabetes, the ability of glucose to stimulate glucose uptake was
found normal in one study (27), while a concentration-dependent defect was found
in another (352).
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The ability of hyperglycemia to increase glucose uptake by pathways which are
distinct from those used by insulin, explain why rates of glucose uptake are either
normal or increased in type 2 diabetic patients under conditions of every-day life
(338). Chronic hyperglycemia induces insulin resistance to glucose utilization, a
phenomenon called glucose toxicity of insulin action (422,526).
Regulation of postprandial glucose concentrations in normal subjects and in pa-
tients with type 2 diabetes
Normally, glucose ingestion increases insulin and decreases glucagon secretion and
suppresses EGO, allowing exogenous glucose to become the predominant source of
glucose utilized (145,231,232,248,399). Approximately 30 %  is taken up by
splanchnic tissues, i.e. the liver and the gut, (145,231,232,248,399), 30-40% is
taken up by muscle (231,232,248,399), and the rest is primarily disposed of by the
brain (248) over a 5-hour period. In muscle ~40 % of the glucose taken up is oxi-
dized, ~40 % is stored as glycogen and the rest is released as lactate, alanine or py-
ruvate (248).
In type 2 diabetes, postprandial suppression of plasma glucagon concentrations and
increase in plasma insulin by glucose are usually blunted (116,476). Again, because
of the combined effects of glucose mass action and insulin resistance, postprandial
forearm muscle glucose uptake in type 2 diabetes has constantly been found to be
similar or even greater than in non-diabetic subjects (52,150,231,338). Mitrakou et
al. have examined the contribution of altered muscle and liver glucose metabolism
to postprandial hyperglycemia in type 2 diabetes (338). They administered an oral
glucose load enriched with [14 C]glucose to 10 type 2 diabetic patients and 10 nor-
mal subjects and measured muscle glucose disposal by determining forearm  bal-
ances of glucose, lactate, alanine, O2  and CO2. In addition, a dual-label isotope
method was used to compare overall rates of glucose appearance (Ra ) and disap-
pearance (Rd ), suppression of EGO and splanchnic glucose sequestration. The in-
crease in postprandial glucose concentrations (PPG) and of glucose Ra in patients
with type 2 diabetes were due to impaired supression of EGO  (Fig. 2).
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Fig. 2. Mean ± SE rates of oral glucose appearance in systemic
circulation, endogenous glucose appearance, total glucose ap-
pearance (endogenous and oral), and the total glucose disap-
pearance in non-diabetic (o; n = 10) and type 2 diabetic patients
(•; n = 10). Modified from ref. (338)
The amount of glucose taken up by muscle was not significantly different between
patients with type 2 diabetes and normal subjects, although a greater amount of the
glucose taken up by muscle in type 2 diabetes was released as lactate and alanine
and less was stored (338). It was concluded that the ability of insulin to suppress
EGO determines the degree of postprandial glycemia. Other studies have also found
that insulin-induced suppression of hepatic glucose release (Fig. 3) and insulin
stimulated muscle glucose uptake are the major factors regulating postprandial glu-
cose metabolism (112,170,405).
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Fig. 3. Mean ± SE plasma glucose (mmol/l) concentrations at
hourly intervals from 0800 to 1600 (breakfast at 0800 and lunch
at 1200) in normal individuals (cont) (•) and patients with type 2
diabetes (o), who are divided in mild and severe (sev) groups, in
severe group insulin concentrations are low and hepatic glucose
production is the main cause of elevated glucose concentrations.
Modified from ref. (405).
2.1.3. Sensitivity of endogenous glucose production to insulin
Measurement of EGO
In humans, EGO has been studied using the hepatic venous catheterization tech-
nique (49,61,141), by tracer methodology (408), by combining both (116,428) and
by NMR (311,424).
The most commonly used glucose tracer for measurement of hepatic glucose pro-
duction is [3-3H]glucose. This tracer is handled by body tissues in a similar manner
to cold glucose (115). The tritium from the 3-position in glucose is lost during gly-
colysis but not during glucose incorporation to and release from hepatic glycogen
(514). The latter process is, however, of no concern when glucose production is
measured under fasting conditions because, even after prolonged infusion of [3-
3H]glucose, stimulation of glycogenolysis with glucagon does not increase the level
of plasma radioactivity (175). Thus, if isotopic steady-state is achieved during infu-
sion of [3-3H], i.e. glucose specific activity can be held constant, the rate of hepatic
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glucose production, in fact EGO, can be accurately calculated by dividing the iso-
tope infusion rate by the specific activity (SA) of glucose (514). However, quite
frequently and especially when rapid fluctuations in the rate of entry of exogenous
or endogenous glucose into the circulation occur, the specific activity of glucose
changes (175). Calculation of the glucose kinetics now becomes dependent on the
use of models that describe glucose kinetics under non-steady-state conditions. Of
these the most commonly used is the modified one-compartment model described
by Steele (447). Because of the inability of this model to describe whole body ki-
netics of glucose accurately, glucose production is underestimated when specific
activity decreases; the greater the deviation from steady-state, the greater the under-
estimation (87,533). This phenomenon explains why physiologically impossible
negative rates of glucose production can be observed, especially when the response
of endogenous glucose production to insulin is determined using the insulin clamp
technique (54,149). More reliable estimates of EGO can be obtained if changes in
the SA of glucose can be minimized (104). Because the concentration of glucose in
plasma and thereby the glucose pool is increased in patients with type 2 diabetes,
the time to reach isotopic steady-state during tracer infusion is prolonged. This is
why the infusion time of [3-3H]glucose should be longer in type 2 diabetic patients
than in normal subjects (87,533).
Normal subjects
Insulin plays a key role in the maintenance of normal glucose tolerance by sup-
pressing EGO during a meal. Complete suppression of EGO by intravenous insulin
has been found at peripheral insulin concentrations of 50-60 mU/l (116,417,540).
Insulin is thought to suppress EGO by a direct effect on the liver rather than via an
extrahepatic effect, although studies in conscious dogs have suggested that insulin
action in the periphery may also be of importance (527). Insulin may also suppress
EGO, at least in part, via a decrease in glucagon secretion (540). Under physiologi-
cal conditions insulin does not inhibit gluconeogenesis but rather diverts gluconeo-
genic flux towards glycogen (81). Insulin effectively suppresses glycogenolysis
(115). Insulin is less important in the regulation of splanchnic glucose uptake (45),
which appears, based on studies performed in dogs, to be regulated primarily by the
arterial-portal glucose gradient and to a smaller extent by glucose mass-action
(116,347,371).
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Obesity and fat distribution
Obesity is associated with decrease in the sensitivity of both EGO and peripheral
glucose uptake to insulin (67,364,392). Hyperinsulinemia and insulin resistance are
more pronounced in upper body obesity (378,379). Visceral adipose tissue has a
higher turnover rate than other adipose tissue depots in both men and women. The
visceral fat is drained via the portal vein to the liver, in contrast to periferal fat de-
pots. The increased lipolytic activity of visceral fat, combined with its anatomical
location, exposes the liver to higher concentrations of FFA than any other organ.
FFA decrease insulin clearance by the liver and increase EGO (144,323). The
causes for interindividual variation of hepatic sensitivity to insulin in obese subjects
as well as in normal subjects are largely unknown.
Type 2 diabetes
Resistance of EGO to suppression by insulin has been a consistent finding  in pa-
tients  with type 2 diabetes (53,147). Plasma glucagon concentrations are inappro-
priately high in relation to prevailing hyperglycemia and hyperinsulinemia in type 2
diabetic patients in the postabsorptive state (477) and may therefore contribute to
the increase in EGO. The contribution of excessive glucagon  to the  increase in
GLN and EGO in type 2 diabetes, has not been examined directly. In type 2 diabe-
tes EGO is increased despite hyperglycemia in the postabsorptive state and directly
correlated with the fasting plasma glucose concentration (59,68,103,117,122,411).
Fasting plasma FFA concentrations also correlate with EGO (189,463).
2.1.4. Cardiovascular disease - the major complication of type 2 diabetes
Epidemiology of coronary heart disease in type 2 diabetes
It has been shown that mortality from cardiovascular disease (CVD) and the inci-
dence of the non-fatal coronary heart disease (CHD) events is 2 to 4 times higher in
patients with type 2 diabetes than in non-diabetic subjects (69, 195, 243, 275, 276,
320, 396, 445 , 480, 485, 493). CVD accounts for 70 % of all deaths in people with
diabetes (273). Diabetic patients without previous myocardial infarction have as
high a risk of myocardial infarction as non-diabetic patients with previous myocar-
dial infarction (195). Diabetic patients with myocardial infarction also have a worse
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prognosis than non-diabetic patients with myocardial infarction (19,337). The risk
of CHD is increased already in the prediabetic state (165,198). Diabetic women
have even a higher risk for CHD than diabetic men when compared to non-diabetic
counterparts (198,275).
Classic cardiovascular risk factors
In the 12 year prospective Multiple Risk Factor Intervention Trial (MRFIT) (445)
CVD death rates were approximately 3 times higher in men with diabetes compared
to men without diabetes (Fig. 4).
Fig. 4. Age adjusted CVD death rates by the presence of number
of risk factors for men screened for MRFIT, with and without dia-
betes at baseline. Modified from ref. (445)
 A significant positive relationship between serum cholesterol and CVD mortality
was observed for both diabetic and non-diabetic men. However, at every concen-
tration of serum cholesterol, the CVD death rate was several times higher in dia-
betic than in non-diabetic men. Results were similar for blood pressure and smok-
ing. Thus, even when all classic risk factors were considered, CVD mortality still
remained 3-fold higher in diabetic than in non-diabetic men. The inability of classic
risk factors to explain increased CDH mortality has been confirmed in several other
studies. Classic risk factors also do not explain the increased cardiovascular risk of
IGT subjects (236). For example in the Whitehall study (166), almost three quarters
of the increased relative risk of deaths from coronary heart disease and stroke in in-
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dividuals with IGT and type 2 diabetes were not explained with risk factors such as
age, blood pressure, obesity, smoking or the serum cholesterol concentration.
Although classic risk factors do not explain excessive mortality for CVD in diabetic
as compared to non-diabetic subjects, classic risk factors are important predictors of
CVD death also in diabetic patients. This was also shown by the UKPDS (475), in
which the major risk factors for CHD in type 2 diabetes were  increased concentra-
tion of low density lipoprotein cholesterol (LDL), a decreased concentration of high
density lipoprotein cholesterol (HDL), hyperglycemia, hypertension and smoking.
Components of insulin resistance and chronic hyperglycemia as cardiovascular
risk factors
Several prospective epidemiological studies have shown that hyperinsulinemia pre-
dicts the risk of CHD in non-diabetic subjects (127,270,289,397). Some cross-
sectional studies have shown that type 2 diabetes patients with atherosclerotic vas-
cular disease (AVD) have higher concentrations of fasting plasma insulin or C-
peptide or higher postglucose plasma insulin concentrations than those without
AVD (419,431,446). In the UKPDS (475) fasting serum insulin concentrations
were positively correlated with the risk of MI but this correlation became non-
significant after adjustment for other risk factors. In contrast to these observations,
in a 10-year follow-up of the "borderline" diabetic group of the Bedford Study, a
low 2-h post-glucose plasma insulin was associated with an increased risk of CHD
events (235). Lehto S et al. (288) have recently shown in a 7-year prospective study
that the predictive value of hyperinsulinemia with respect to death from CHD was
independent of conventional cardiovascular risk factors but not of risk factors clus-
tering with hyperinsulinemia. By applying factor analysis and principal component
analysis it was shown that  the "hyperinsulinemia cluster" (a factor having high
positive loading for BMI, triglycerides and insulin; and high negative loading for
HDL cholesterol) was predictive of death from CHD in type 2 diabetic patients.
Kaukua et al. got similar results (247). Other studies have also emphasized the as-
sociation of hyperinsulinemia with several cardiovascular risk factors (194). These
data suggest that causes of the insulin resistance syndrome, such as obesity and
consequences of insulin resistance such as hypertriglyceridemia and a low HDL
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cholesterol concentration are more important than hyperinsulinemia itself as risk
factors of cardiovascular disease (192).
Many studies have indicated that hyperglycemia is an independent predictor for risk
of CVD in type 2 diabetes (258,269,273,287). Many potential mechanisms may ex-
plain why poor metabolic control of diabetes predicts CHD events (63,396). Hy-
perglycemia is related to renal disease, microangiopathy and abnormalities in lipo-
protein particle composition, which in turn are known to be atherogenic. Chronic
hyperglycemia causes non-enzymatic glycosylation of all apolipoproteins (63),
which may impede LDL recognition and consequent decreased clearance by the
LDL receptor (513), and enhance LDL uptake by macrophages (63,326,513). Hy-
perglycemia may also accelerate trombus formation among diabetic patients (93)
and it has been reported to cause irreversible glycation of proteins in the arterial
wall, which may also contribute to the development of vascular complications
(314).
Dyslipidemia
Two major abnormalities characterize lipoprotein metabolism in type 2 diabetes:
fasting and postprandial concentrations of triglyceride-rich lipoproteins, especially
very-low-density lipoproteins (VLDL) are higher and those of HDL cholesterol
lower than in non-diabetic subjects (458,460).
In addition, an increase in atherogenic small dense LDL particles (lipid-poor and
protein enriched) characterize dyslipidemia in type 2 diabetes (460). A preponder-
ance of small dense LDL is associated with insulin resistance (406) and with the
risk of myocardial infarction and CHD in non-diabetic subjects (35,105,167). In
many prospective studies hypertriglyceridemia has been shown to be a predictor of
CHD events and mortality (155,274,287). A meta-analysis of prospective studies
suggested that hypertriglyceridemia is a risk factor of CHD even independent of
HDL (212).
Obesity and fat distribution
Obesity is an important modifiable risk predictor for type 2 diabetes (254). Many
cross-sectional studies have shown that excess abdominal fat in type 2 diabetic pa-
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tients correlates with CHD events and other CHD risk factors (30,47,488). Pro-
spective studies such as Quebec Cardiovascular Study have shown that the cluster
of metabolic abnormalities found in patients with especially upper body obesity
substantially increases the risk of CHD (126,281).
Coagulation and fibrinolysis
Fibrinogen has emerged as an important and independent predictor of cardiovascu-
lar disease and coronary events in a number of prospective studies in non-diabetic
patients (203,244,333,524). Concentrations of factor VII, von Willebrand factor
(vWF), tissue plasminogen activator (t-PA) antigen and plasminogen activator in-
hibitor-1 (PAI-1) have been identified in various studies as independent and signifi-
cant predictors of myocardial infarction, fatal coronary events and severity of coro-
nary disease in non-diabetic patients (6,201,333). Abnormalities of both coagula-
tion and fibrinolysis have been described in type 2 diabetes with increased concen-
trations of fibrinogen (366), factor VII (164), vWF (101), t-PA antigen (179) and
PAI-1 (148,179,184,330) .
Many cross-sectional studies conducted in different populations have shown that
PAI-1 and t-PA antigen, which represents t-PA/PAI-1 complexes, are strongly cor-
related with  insulin, triglycerides, HDL cholesterol, BMI, W/H and blood pressure
i.e. causes or consequences of the insulin resistance, and that the improvement of
insulin resistance corrects metabolic abnormalities and concentrations of the fibri-
nolytic parameters (25, 33, 201, 241, 283, 439, 457, 486). These abnormalities in
fibrinolytic and coagulation parameters could thus contribute to the increased risk
of CHD in type 2 diabetes.
Hypertension
Hypertension is one of the classic risk factors for CHD and stroke (91,309), and is
more common in people with type 2 diabetes than in the general population
(7,43,243). Modan et al. initially, from a cross-sectional study, suggested that hy-
perinsulinemia is associated with hypertension independent of glucose tolerance or
obesity (340). Some cross-sectional studies have supported the same association
between insulin concentrations and hypertension (138,146,509). On the other hand,
some epidemiological studies (65,131,345) have not found an independent relation-
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ship between markers of insulin resistance and hypertension. In three prospective
studies, insulin or insulin resistance predicted the incidence of hypertension
(303,356,438) while in one insulin predicted the incidence of hypertension in lean
but not in obese subjects (193).
In UKPDS there was an important association between CHD and blood pressure
and this association persisted after adjustment for other risk factors of CHD: age,
sex, ethnic group, glycemia, lipid concentrations, smoking and albuminuria (15,22).
Taken together these data imply that hypertension is an important risk factor for
CHD in type 2 diabetes, and that the mechanisms  explaining the increased preva-
lence of hypertension in patients with type 2 diabetes are still unclear.
Novel markers of cardiovascular risk in type 2 diabetes
Urinary albumin excretion
Microalbuminuria is a risk predictor of CHD in patients with type 2 diabetes (129,
308, 354, 487), and in non-diabetic subjects (106, 229, 541). In many studies mi-
croalbuminuria and albuminuria have been shown to be associated with many other
CHD risk factors (90, 210, 270, 328). Haffner et al. have shown that normotensive
subjects with microalbuminuria had significantly higher triglyceride and insulin
concentrations during an oral glucose tolerance test than normotensive subjects
without microalbuminuria suggesting an increased atherogenic risk factor pattern in
normotensive subjects with microalbuminuria (200). Hyperinsulinemia and micro-
albuminuria are also strong predictors for CHD events in elderly non-diabetic sub-
jects (270).
A number of different mechanisms have been postulated to link microalbuminuria
to CHD  including insulin resistance (186, 353). The greater the albumin excretion
rate or blood pressure, the greater the insulin resistance in type 2 diabetes (405).
Subjects with microalbuminuria have significantly higher insulin concentrations
than the normoalbuminemic subjects (186, 270), a generalized increase in vascular
permeability (110), an atherogenic lipoprotein pattern (110, 328) and endothelial
dysfunction (245, 332, 449). The causal relationship between microalbuminuria and
vascular functions is not established. Possibly microalbuminuria is just a sensitive
marker of vascular damage.
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Changes in oxidative stress
Free radicals are continuously produced during aerobic metabolism (73). Incom-
plete scavenging of reactive radicals leads to oxidation of cellular lipids, proteins,
nucleic acids and glycoconjugates (48). An imbalance between protective antioxi-
dants and increased free radical production results in oxidative stress. Oxidation of
circulating LDL has been linked to the initiation and progression of atherosclerosis
and ultimately to the pathogenesis of CHD (450).
Many studies have suggested that oxidative stress is increased in type 2 diabetes   
(20, 73, 74, 90, 342, 376, 456, 467) and contribute to the increased incidence of
CHD in type 2 diabetes.
Endothelial dysfunction
Vascular endothelium has a central and primary role in the atherogenic process
(239, 326, 327). Normally endothelium actively regulates vascular tone and perme-
ability, the balance between coagulation and fibrinolysis, the composition of the
subendothelial matrix, the extravasation of leukocytes and the proliferation of vas-
cular smooth muscle and renal mesangial cells. To carry out these functions, the
endothelium produces a variety of regulatory mediators, such as nitric oxide,
prostanoids, endothelin, angiotensin II, t-PA, PAI-1, vWF, adhesion molecules and
cytokine (388). At the in vivo level, endothelial cell products can be measured in
the circulation, with altered concentrations potentially reflecting endothelial activa-
tion and dysfunction (448). Endothelial dysfunction can also be measured by meas-
uring the ability of endothelium dependent agents to reduce vasodilatation (84, 88,
375).
Endothelial dysfunction has been found to characterize non-diabetic insulin resis-
tant obese subjects (277), patients with IFG (492) and in young normotensive first-
degree relatives of type 2 diabetic patients in association with insulin resistance
(41). Multiple factors could contribute to endothelial dysfunction in type 2 diabetic
subjects compared with non-diabetic subjects matched for traditional causes of en-
dothelial dysfunction, such as smoking habits, LDL cholesterol concentrations and
blood pressure. Such factors include those known to be associated with increased
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cardiovascular risk, such as chronic hyperglycemia (258, 501), hyperinsulinemia
independent of insulin resistance (426), insulin resistance and its consequences
(405).
Adhesion molecules as markers of endothelial activation
Cellular adhesion molecules have been shown to participate in cell emigration, sig-
naling functions and other vascular physiological responses (159, 160). Shedding of
cellular adhesion molecules from the surface of activated endothelium and macro-
phages results in measurable plasma concentrations of soluble cellular adhesion
molecules (384), which are increased in many inflammatory and immunological
conditions characterized by endothelial dysfunction (256, 358, 523, 543).
There are four classes of adhesion molecules (160): 1) Integrins; 2) The immuno-
globulin gene superfamily, the prototypic members of which are vascular cell adhe-
sion molecule-1 (VCAM-1), intercellular adhesion molecule-1 and -2 (ICAM-1, -2)
and platelet -endothelial adhesion molecule (PECAM), which all have been impli-
cated in atherogenesis (393); 3) Cadherins; 4) Selectins, of which three types have
been identified: E-, P- and L-selectin. E-selectin is expressed exclusively on endo-
thelial cells (159).
In vitro, hyperglycemia promotes leukocyte adhesion to endothelial cells through
up-regulation of cell-surface expression of E-selectin, ICAM-1 and VCAM-1 (341).
Stimulation of endothelial cells with AGE also increases expression of these adhe-
sion molecules (268). It has been shown that in non-diabetic subjects the degree of
insulin resistance significantly correlates with concentrations of sE-selectin (80). In
type 2 diabetic patients, concentrations of serum sE-selectin have been increased in
most (23, 95, 97, 125, 451) , although not all (128, 242) comparisons with normal
subjects, and have correlated with glycemia in five studies  (23, 95, 97, 125, 451).
Most comparisons between type 2 diabetic patients and normal subjects have
shown increased serum sICAM-1 concentrations in type 2 diabetic patients (97,
125, 128, 242, 271). In seven studies (23, 42, 108, 125, 242, 297, 451) serum
sVCAM-1 concentrations have been increased in type 2 diabetic patients compared
with normal subjects, while no difference was found in four studies (42, 95, 128,
242). A correlation with glycemic control and sVCAM-1 was found in one study
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(297) but not in other studies (23, 42, 242, 367, 451). These cross-sectional data
suggest that sE-selectin may be a more sensitive indicator of hyperglycemia-
induced endothelial activation in vivo than sVCAM-1 or sICAM-1, although the
expression of all three is regulated by glucose in vitro.
Data on the effects of various treatments on circulating adhesion molecules in type
2 diabetes are very limited. A positive correlation with glycemic control was re-
ported in two short-term studies (23,94), which, respectively, included 16 and 34
patients with type 2 diabetes and lasted 2 and 12 weeks. There are, however, no
data on long-term effects of insulin therapy on these markers of vascular inflamma-
tion or endothelial activation.
Regarding the relationship between circulating adhesion molecules and CHD,
sVCAM-1 has been reported to be increased in patients with type 2 diabetes with
overt macrovascular disease compared with patients who are clinically free of CHD
(242,367) and its concentration have been reported to correlate with intima-media
thickness (367). sVCAM-1 concentrations have also been shown to correlate with
the extent of atherosclerosis in non-diabetic subjects (381). sE-selectin concentra-
tions have been shown to predict restenosis after angioplasty (51) and sICAM-1
concentrations predict the risk of future myocardial infarction in apparently healthy
men (416).
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2.2 GENERAL PRINCIPLES IN THE TREATMENT OF TYPE 2
DIABETES
The overall objective of treatment for type 2 diabetes is to prevent acute and
chronic complications of diabetes while maintaining high quality of life. Because
patients with type 2 diabetes have a 2 to 4-fold increased mortality from CVD, the
ultimate goal of all therapies in type 2 diabetes is to reduce this burden.
2.2.1. Diet and exercise
Lifestyle modifications are important components of the treatment of type 2 diabe-
tes.
Diet
There are at present no data which would have documented beneficial effects of
diet therapy on cardiovascular outcome in patients with type 2 diabetes, on the
other hand for IGT patients such data exists (473). Weight loss improves insulin
sensitivity in obese non-diabetic subjects (177). Weight reduction in obese type 2
diabetic subjects has also been shown to ameliorate insulin resistance, but may not
restore β-cell dysfunction (39,158). Although weight loss theoretically is the best
treatment for type 2 diabetes, results obtained so far have not been particularly con-
vincing. The largest study examining effects of diet intervention on glucose control
and other parameters is the UKPDS, which was a randomized, controlled 11-year
trial on the effects of improved metabolic control on complications in type 2 dia-
betes. After initial diet therapy, 4209 asymptomatic patients who remained hyper-
glycemic were assigned to either a conventional therapy policy, which primarily
consistent of diet alone, or to an intensive therapy policy, which  aimed at main-
taining fasting plasma glucose concentrations less than 6.0 mmol/l, with assignment
to primary therapy with sulphonylurea or insulin or metformin. The initial diet ther-
apy substantially reduced plasma glucose concentrations and serum triglycerides,
marginally decreased total cholesterol and increased HDL cholesterol concentra-
tions (319). However, the effect of the diet was transient since glycemic control
progressively deteriorated during the study, even in the individuals who were using
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antihyperglycemic therapies (10). In addition to the UKPDS, data are sparse re-
garding long-term effects of weight loss. In the study of Uusitupa et al., 12 months
intensiv diet education of recently diagnosed patients with type 2 diabetes resulted
in improved glycemic control compared to a conventional treatment group. Only
the intensively advised group lost weight and showed beneficial changes in serum
lipids and lipoproteins (479,483). Weight reduction and a decrease in saturated fat
intake appeared to be the main determinants of successful treatment results. During
the second year of observation, both groups gained weight and glycemic control
deteriorated. Despite this, a greater proportion of patients in the intensive as com-
pared to the control group still was in good metabolic control. The intensively
treated group also used less frequently antihyperglycemic agents than the conven-
tional group (479,483). Similar results have been found also in other, usually more
short-term, studies (251,372,484,505,507,508,510,511). A high intake of dietary fi-
ber may also improve glycemic control, and lower plasma lipid concentrations and
systolic or diastolic blood pressure in patients with type 2 diabetes (77,482). These
effects are quite weak, however. Use of pharmacological agents such as orlistat
may help to sustain weight loss (vide infra).
Cessation of smoking is also an important component in all lifestyle intervention
programs.
Exercise
Prospective epidemiological data suggest that physical activity can reduce mortality
from cardiovascular disease in patients with type 2 diabetes (502). In the Aerobic
Center Longitudinal Study the association between low cardiorespiratory fitness
and physical activity with total mortality in 1263 men with type 2 diabetes was
studied. After adjustment for age, pre-existing and family history of cardiovascular
disease, fasting glucose and cholesterol concentrations, overweight and hyperten-
sion, type 2 diabetic men in the low-fitness group had a risk for all-cause mortality
of 2.1 compared to those in the high-fitness group. The majority of deaths were at-
tributable to cardiovascular disease (502). Intervention studies which would have
documented physical acitivity to reduce cardiovascular disease in patients with type
2 diabetes are currently lacking.
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Regarding the mechanisms which might underlie the seemingly beneficial cardio-
vascular effects, physical training is known to improve insulin sensitivity of glu-
cose uptake in skeletal muscle (263), and in many but not all of short-term training
studies, potentially beneficial effects on serum lipids and blood pressure have been
observed (525). In non-diabetic subjects, physical training has been consistently
shown to enhance fibrinolysis by decreasing concentrations of PAI-1 (525). Data on
training effects on such parameters are limited in type 2 diabetes.
2.2.2. Mechanism of action of oral agents
Fig. 5. shows mechanisms of action of OAD and Table 2 compares properties of
various OAD.
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Table 2. Properties of various OAD
Dose
range1
(mg)
Doses per day/
dose increase (mg)
HbA1c-
reduction
(%)2
Effect
on
weight
Hypo-
glycemias
Protein
binding
%
Active me-
tabolites
Liver glucose produc-
tion inhibitors
Metformin 500-2500 2/500 1.5-2.0 NO NO NO NO
Insulin secretion en-
hancers
Sulphonylureas
1st generation
Tolbutamide 500-2000 2/500 ↑↑ ↑ 80-99 ND
Chloropropamide 125-500 1/125 ↑↑ ↑↑ >98 Yes
2nd generation
Glibenclamide 1.75-14 2/1.75 1.5-2.0 ↑↑ ↑↑ >98 Yes
Glipizide 2.5-15 1/2.5 1.5-2.0 ↑↑ ↑↑ >98 Yes
Gliclazide 80-320 2/80 1.5-2.0 ↑↑ ↑↑ 96 NS
3rd generation
Glimepiride 1-8
(4-6)
1/2 1.5-2.0 ↑↑ ↑↑ >98 Yes
Glinides
Repaglinide 0.5-4.0
(12)
3-4/1 1.5-2.0 ↑↑ ↑↑ >98 Yes
Nateglinide 120-360 3/30-120 1.5-2.0 ↑↑ ↑ 97 Yes
Insulin sensitizers
Glitazones
Pioglitazone 7.5-45 1/15 1.5-2.0 ↑↑↑ NO >97 Yes
Rosiglitazone 2-8 2/2 1.5-2.0 ↑↑ NO 99.8 Yes
Carbohydrate absorp-
tion affecting
Alphaglucosidase
blockers
Acarbose 100-300 3/50 0.5-1.0 NO NO NO NO
Miglitol 100- 300 3/50 0.5-1.0 NO NO NO NO
Absorption inhibitors
Guar gum 5-15 g 3/2.5 g 0.5 NO NO NO NO
1 Recommended maximum dose in bold
2  With maximum dose
ND = not exactly known
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           Metformin
Metformin lowers blood glucose by inhibiting EGO (222). About 50 - 60 % of in-
gested metformin is absorbed. It is not bound to plasma proteins and is very little
metabolized (38). Over 90 % is eliminated rapidly by the kidneys (38). Metformin
induces less weight gain than other oral agents (118). Side effects of metformin in-
clude slight gastrointestinal dysfunction and slight danger of lactic acidosis (38),
but it can cause vitamin B12 malabsorption, which can be reversed by increased in-
take of calcium (46).
Sulphonylureas
Sulphonylureas (SU) stimulate insulin secretion by closing the ATP dependent K+-
channels in β-cells (315,440). Differences between various sulphonylureas are
shown in Table 2. Of the 2nd generation sulphonylureas glibenclamide is long-
acting and the absorption of glibenclamide is rather slow and varies  between indi-
viduals (225). It is completely metabolized (142) and half of a given dose of
glibenclamide is eliminated by renal excretion of metabolites and a significant por-
tion is excreted through bile. Although renal insufficiency should not alter the
elimination rate of this very lipophilic drug, it may nevertheless increase the risk of
hypoglycemia (142). Glipizide is also completely metabolized and the metabolites
are inactive (142). It is relatively rapidly acting and also one of the most short-
acting (142,335). Renal insufficiency does not seem to alter the elimination rate of
glipizide.
Gliclazide is also a rapid- and short-acting sulphonylurea. Most of the gliclazide is
eliminated by excretion of inactive metabolites through the kidneys, and a small
fraction is eliminated by the bile (142). Gliclazide differs from other sulphonylureas
in that it has antioxidant properties, the clinical significance of which is uncertain
(92,180,237,350).
Glimepiride is a 3rd generation sulphonylurea which can be taken once per day
(423). Glimepiride does not bind to ATP dependent K+- channels outside β-cells,
such as those of the myocardial or vascular smooth muscle cells (443). Hypogly-
cemia may be a smaller treatment problem with glimepiride compared to gliben-
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clamide (133). Main side effects of SU are hypoglycemia and gastrointestinal trou-
bles and very seldom cholestatic hepatitis (335).
Glinides
Repaglinide and nateglinide are novel insulin secretagogues, which differ from the
sulphonylureas in their molecular structure, time action profile and excretion
mechanisms (40,134). They stimulate the prandial release of insulin by inhibiting
the ATP dependent K+- channels in β-cells, and appear to bind to a different re-
ceptor site from sulphonylureas (40,134). They are rapidly absorbed and elimi-
nated, which contributes to a fast onset and offset of action (40,134). Glinides are
almost entirely metabolized. Metabolites of repaglinide are excreted mostly in the
bile and those of nateglinide in the urine. In comparative clinical trials in patients
with type 2 diabetes mellitus, nateglinide 120 mg and repaglinide 4 mg three times
daily before meals provided similar glycaemic control as glibenclamide 10 mg/day
(213).
Glitazones
Glitazones are peroxisome proliferator-activated receptor gamma (PPAR-γ) ago-
nists. PPAR-γ is a nuclear receptor that regulates the expression of several genes
involved in metabolism. This receptor controls adipocyte differentation, lipid stor-
age, and insulin sensitisation (436). Besides metabolic activities, glitazones have ef-
fects as diverse as the control of host defense, cell proliferation, and tumorigenesis
(228,360,436). The reduction of hyperglycemia is associated with a near normali-
zation of the rate of EGO and a 40-60% increase in insulin mediated glucose dis-
posal as measured by the glucose clamp technique (357). There are now two glita-
zones available, rosiglitazone and pioglitazone. When compared 8 mg rosiglitazone
(twice a day for monotherapy) and 45 mg pioglitazone once daily the decrease in
HbA1c was similar (near 2 %). Ppioglitazone reduces LDL and triglycerides
whereas rosiglitazone slightly increases them (252). HDL increased with pioglita-
zone treatment whereas there was no change with rosiglitazone (252). Weight gain
was greater with pioglitazone and oedema was the same with both medications
(252). Adverse effects are weight gain, edema and lowering of hemoglobin (163).
This prohibits the use of these medications in patients with cardiac insufficiency.
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Acarbose and guar gum
Acarbose inhibits in a dose dependent manner, competitively and reversibly, intes-
tinal α-glucosidases and in addition displays an inhibitory effect on pancreatic α-
amylase (265). Consequently, acarbose inhibits intestinal digestion of carbohy-
drates, especially of starch and sucrose. This effect leads to a delayed absorption of
monosaccharides in distal parts of the small intestine (265) and results to a decrease
in PPG and insulin concentrations, FBG is decreased only to a minor degree (265).
Less than 2 % of acarbose is absorbed from the gut. Acarbose reduces HbA1c about
0.5 % (216,280) and HbA1 1.4 % (220). Gastrointestinal side effects are the most
common and for example occurred in UKPDS 8 to 30 % (216).
Guar gum is a soluble dietary fiber which is used for lowering serum total choles-
terol in patients with hypercholesterolemia and for lowering blood glucose in type 2
diabetic patients (481,482,494).
Orlistat
Orlistat is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat ab-
sorption by approximately 30 % (307). Orlistat is minimally absorbed. Adverse ef-
fects were primarily, and almost exclusively, gastrointestinal. Due to ability to
block fat absorption, orlistat also has the capability to inhibit absorption of fat-
soluble vitamins (307).The ability of orlistat to improve glycemic control is strictly
proportional to the amount of weight loss achieved. In  studies with orlistat 5 - 10
% and >10 % changes in body weight were associated with 1 and 1.5 - 2 % de-
crease in HbA1c (214,298).
2.2.3. Effect of oral agents on risk factors and markers of micro- and macrovas-
cular complications and hypoglycemia
Effects of OAD on various risk factors and markers of complications have been in-
cluded in Tables 3 - 6. These Tables include studies after 1980, which have been either
placebo controlled or have had an active comparative drug, contain data as HbAI or
HbA1c, and have lasted at least 3 months.
Table 3. Effects of metformin containing regimens on various markers of cardiovascular risk. Studies,  performed after
1980 and which have been either placebo controlled or have  had an active comparator drug, contain data as
HbA I or HbA1c, and have lasted at least 3 months, are included
Study Experimental
Comparator drug
Concomitant
drug
HbA1c
change
%
FBG change
mmol/l
S-FFA S-Tg S-Chol S-HDL S-LDL Blood
Pressure
Weight S-ins
deFronzo et al.
(118)
Protocol 1
Metformin
Placebo
Protocol 2
Metformin
Metformin
Glipenclamide
Glibencl.
↓1.5
0 *
↓0.4
↓1.7
↑0.2
↓3.1
0*
↓0.1
↓3.5
↑0.8
NS
NS
NS
NS
↓
↓
↓
NS
NS
NS
NS
NS
↓
↓
↓
NS
Dornan et al.
(130)
Metformin
Placebo
↓1.4
↑1.5
↓3.3
↓2.6
NS
NS
↓
NS
NS
NS
NS
NS
NS
NS
Hermann et al.
(205)
(206)
Metformin
Glibenclamide
Metformin Glibencl.
↓0.9
↓1.3
↓2.3
↓2.1
↓2.1
↓5.4
NS
NS
NS
NS
NS
NS
↓
↑
NS
↑
↑
Inzucchi  et al.
(227)
Metformin
Troglitazone
Metformin Troglitazone
NS
NS
↓1.2
↓3.2
↓2.9
↓2.3
NS
NS
NS
Josephkutty  et al.
(240)
Metformin
Tolbutamide
↑0.6
↓0.1
↑1.1
 ↑0.02
NS
NS
NS
NS
NS
NS
↓
↑
NS
NS
Lalor  et al.
(279)
Metformin
Guar gum
Placebo
↓2.8
↓1.9
NS
NS
NS
↓
NS
NS
NS
↓
Nagi et al.
(349)
Metformin
Placebo
↓1.5
   ↓0.2
↓3.1 ↓ ↓ NS ↓ NS
NS
NS NS
Schneider et al.
(435)
Metformin
Placebo
↓0.7
↓0.2
↓ ↑ ↓
* Mean change during placebo set as 0%.
↓ Significant decrease.
↑ Significant increase.
NS No significant change.
Glibencl. = glibenclamide
Table 4. Effects of regimens containing sulphonylureas or glinides on various markers of cardiovascular risk. Studies
performed after 1980 and which have been either placebo controlled or have  had an active comparator drug, contain
data as HbA I or HbA1c, and have lasted at least 3 months, are included
Study Experimental
Comparator drug
Concomitant
drug
HbA1c
change%
FBG change
mmol/l
S-FFA S-Tg S-Chol S-HDL S-LDL Blood
Pressure
Weight S-ins
Amador-Licona et
al.
           (28)
Glibenclamide
Metformin
↓0.8
↓0.9
NS
↓
NS
↓
↑
↑
NS
↓
NS
↓
NS
↓
Pagano et al.
(370)
Glibenclamide
Miglitol
↓1.2
↓0.8
↓1.1
↑0.9
Salman et al.
(429)
Gliclatzide
Acarbose
↓1.8
↓2.2
↓2.0
↓2.6
NS
↓
↓
↓
NS
↓
↑
NS
Birkeland et al.
(57)
Glipizide
Glibenclamide
Placebo
↓0.5
↓0.7
↑0.2
↓0.8
↓0.9
↑1.1
↑
↑
NS
Horton et al.
(218)
Nateglinide
Metformin
Nateglinide
Placebo
Metformin
↓0.5
↓0.8
↓1.4
↑0.5
↓0.7
↓1.6
↓2.4
↑0.4
NS
NS
NS
NS
Goldberg  et al.
(176)
Repaglinide
Placebo
↓0.5
↑1.1
↓1.7
↑1.7
NS
NS
NS
NS
NS
NS
NS
NS
NS
↓
↑
NS
Marbury et al.
(321)
Repaglinide
Glibenclamide
  ↓1.5*
  ↓1.1*
  ↓1.9*
  ↓0.5*
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
↑*
↑*
Moses et al.
(343)
Repaglinide
Metformin
Repaglinide Metformin
↓0.4
↓0.3
↓1.4
↑0.5
↓0.3
↓2.2
NS
NS
NS
NS
NS
NS
↑
NS
NS
↑
↑
NS
↑
NS
NS
     ↑
NS
↑
   ↑
NS
↑
Landgraf et al.
(282)
Repaglinide
Glibenclamide
↓0.3
↓0.4
NS
NS
NS
NS
NS
NS
NS
NS
Raskin et al.
(403)
Repaglinide
Troglitazone
Repaglinide Troglitazone
↓0.8
↓0.4
↓1.7
↓2.4
↓2.8
↓4.4
↑
↑
↑
Wolffenbuttel et al.
(517)
Repaglinide
Glibenclamide
Repaglinide*
Glibenclamid*
↓0.6
↓0.5
↓1.0
↓2.4
↓0.1
↓0.2
NS
NS
NS
NS
NS
NS
↓
↓
*  Pharmacotherapy-naive patients, ↓ significant decrease, ↑ significant increase, NS no significant change
Table 5. Effects of glitazones containing regimens on various markers of cardiovascular risk. Studies,
 performed after 1980 and which have been either placebo controlled or have  had an active comparator drug, contain
data as  HbA I or HbA1c, and have lasted at least 3 months, are included
Study Experimental
Comparator drug
Concomitant
drug
HbA1c
change
%
FBG change
mmol/l
S-FFA S-Tg S-Chol S-HDL S-LDL Blood
Pressure
Weight S-ins
Fonseca et al.
(152)
Rosiglitazone
4mg
8mg
Placebo
Metformin
Metformin
Metformin
↓1.0
↓1.2
↓2.2
↓2.9
↓
↓
NS
NS
↑
↑
↑
↑
↑
↑
↑
↑
↓
↓
Phillips et al.
(383)
Rosiglitazone
4mg o.d.
2mg b.i.d.
8mg o.d.
4mg b.i.d.
Placebo
↓0.8
↓0.9
↓1.1
↓1.5
NS
↑
↑
↑
↑
NS
↑
↑
↑
↑
↑
↑
↑
↑
↑
↑
↑
↑
NS
↑
↑
↑↑
↑↑
Wolffenbuttel
(516)et al.
Rosiglitazone
1mg
2mg
Placebo
SU
SU
SU
↓0.6
↓1.0
NS
↓1.35
↓2.44
↓
↓
↑
↑
↑
↑
NS
↑
↑
NS
NS
↑
NS
↓
↓
NS
Aronoff et al.
(32)
Pioglitazone
15mg
30mg
45mg
Placebo
↑0.3
↓0.3
↓0.9
↑0.7
↓1.7
↓1.8
↓3.1
↓0.5
↓
↓
↓
↑
NS
↑
↑
↑
↑
↑
↑
NS
↑
NS
↑
↑↑
Imano et al.
(226)
Troglitazone
Metformin
↓0.6
↓0.9
↓2.1
↓0.9
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Miyazaki et al.
(339)
Pioglitazone
Placebo
SU
SU
↓1.7
NS
↓2.8
↑1.4
↓
NS
↓ NS
NS
NS
NS
NS
NS
↑
NS
NS
NS
Iwamoto et al.
(230)
Troglitazone
Placebo
SU
SU
↓0.7
↑0.2
↓1.6
↑0.2
↓
NS
NS
NS
NS
NS
NS
NS
↑
NS
Einhorn et al.
(135)
Pioglitazone
Placebo
Metformin
Metformin
↓0.8
NS
↓2.1 ↓ ↑ ↑ ↑
TABLE 5 CONTINUED
Study Experimental
Comparator drug
Concomitant
drug
HbA1c
change
%
FBG change
mmol/l
S-FFA S-Tg S-Chol S-HDL S-LDL Blood
Pressure
Weight S-ins
Kipnes et al.
(253)
Pioglitazone
15mg
30mg
Placebo
SU
SU
↓0.9
↓1.3
NS
↓2.2
↓3.2
NS
↓
↓
NS
↑
↑
NS
↑
↑
↑
↑
Fonseca et al.
(153)
Troglitazone
100mg
200mg
400mg
600mg
Placebo
↑0.1
↓0.4
↓0.7
↓1.1
↓2.3
↓2.8
↓3.3
↓
↓
↓
↓
↓ ↑
↑
↑
↑
↑
NS
NS
NS
NS
Horton et al.
(219)
Troglitazone
200mg
400mg
600mg
Glipenclamide
Troglitazone
200mg
400mg
600mg
Glibencl.
Glibencl.
Glibencl.
↑1.9
↑0.9
↑0.9
↑0.9
↓0.7
↓0.9
↓0.8
↑2.3
↑1.1
↑0.6
↑1.3
↓1.7
↓2.1
↓3.1
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
↑
↑
↑
NS
NS
NS
NS
NS
NS
↑
NS
NS
NS
NS
↑
NS
↑
NS
NS
NS
NS
NS
NS
NS
NS
↑
↑
↑
↓
↓
↓
↓
Yale et al.
(522)
Troglitazone
Placebo
Gliben.+met.
Gliben.+met.
↓1.4
NS
↓2.7
NS
NS
NS
NS ↑ ↑ ↑
NS
↓
↓ Significant decrease.
↑ Significant increase.
NS No significant change.
SU sulphonylurea
Glibencl.=Gliben.=glibenclamide
Met.=metformin
Table 6. Effects of acarbose and orlistat containing regimens on various markers of cardiovascular risk. Studies,  per-
formed after 1980 and which have been either placebo controlled or have  had an active comparator drug, contain data as
HbA I or HbA1c, and have lasted at least 3 months, are included
Study Experimental
Comparator drug
Concomitant
drug
HbA1c
change
%
FBG change
mmol/l
S-FFA S-Tg S-Chol S-HDL S-LDL Blood
Pressure
Weight S-ins
Coniff et al.
(100)
Acarbose
Placebo
↓0.6 ↓0.9 NS NS NS ↓
Coniff et al.
(99)
Acarbose
100mgx3 t.i.d.
200mgx3 t.i.d.
300mgx3 t.i.d.
Placebo
↓0.8
↓0.7
↓1.1
NS
↓0.4
↓1.1
↓0.9
NS
↓
NS
NS
NS
↓ ↓
Hanefeld
(202)
Acarbose
Placebo
↓0.7
0 *
↓1.4
↓0.8
↓ NS
NS
NS
NS
↓
Hotta et al.
(220)
Acarbose
Placebo
↓1.4
↓0.4
Hofman et al.
(216)
Acarbose
Placebo
↓0.5
NS
NS NS
Hollander et al.
(214)
Orlistat
Placebo
SU
SU
↓0.3
↑0.2
↑1.0
↑1.2
↓ ↓ ↓ ↓↓
↓
↓
↑
Lindgarde et al.
(298)
Orlistat
Placebo
↓2.7
↓0.5
↓ ↓ ↓ ↓↓
↓
Lam et al.
(280)
Acarbose
Placebo
SU &
Metformin
SU &
Metformin
↓0.5
NS
NS
NS
NS
NS
NS
NS
NS
NS
↓
NS
NS
NS
↓ Significant decrease.
↑ Significant increase.
NS No significant change.
* Mean change during placebo set as 0%.
SU sulphonylurea
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Glycemic control
Chronic hyperglycemia is a significant predictor of both micro- and macrovascular
complications (12,13,14), without any glycemic threshold for either type of compli-
cation (273). In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (258)
a 1 % increase in HbA1c  increased the risk of developing retinopathy over 10 years
by 60 to 70 % and the risk of death from ischaemic heart disease by 10 %. In the
UKPDS, an increase of HbA1c from 6 to 10 % increased the risk of retinopathy 10-
fold but the risk of myocardial infarction only 2-fold. This suggests that chronic
hyperglycemia is a weak risk predictor of macrovascular disease compared to mi-
crovascular disease. On the other hand, a retinal photography is a far more sensitive
tool to detect harmful effects of chronic hyperglycemia than is myocardial infarc-
tion, which represents  the end point of a long silent atherothrombotic process.
Serum free fatty acids, lipids and lipoproteins
In many (75,113,118,174,259,348,373,435) although not all (66,154) studies met-
formin slightly has decreased triglycerides and serum cholesterol concentrations
and increased HDL cholesterol. In some studies metformin has been shown to de-
crease also LDL cholesterol concentrations (113,215,344,400,521).
Improved glycemic control with SU treatment slightly lowers plasma total choles-
terol, total triglyceride, VLDL cholesterol and triglycerides, and LDL cholesterol
and apolipoprotein B (462). Improved blood glucose control in SU-treated type 2
diabetic patients is associated with either moderate increase (442) or no change
(462) in HDL levels; however, HDL was not normalized even when plasma cho-
lesterol and triglycerides were normal (461). In some (64,302) but not all (185,223)
studies HDL cholesterol was lower in patients treated with SU rather than with in-
sulin, despite comparable glycemic control.
Glitazones also induce changes in serum lipids and lipoproteins (98,224). The ef-
fects appear to be drug rather than class-specific. This conclusion is weakened by
lack of data directly comparing different drugs in the same study. In pioglitazone
studies (32, 135, 253, 339), pioglitazone reduced FFA and triglycerides and in-
creased HDL, in LDL there was a little increase (135) or no significant change. Ro-
siglitazone has been shown to increase total serum cholesterol, LDL and HDL and
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to decrease triglycerides (152, 377, 383, 516), but the decrease is less than with
pioglitazone. All glitazones decrease serum FFA concentrations (135, 153, 310,
339, 437, 516). Orlistat, by inhibiting pancreas lipase, inhibit fat absorption and re-
duces significantly total cholesterol and especially LDL cholesterol (214, 298).
Blood pressure
Data on the effects of antihyperglycemic therapies on blood pressure are sparse
(Tables 3 - 6) and do not allow any firm conclusions to be drown.
Coagulation and fibrinolysis
Data are also sparse regarding effects of antihyperglycemic therapies on markers of
coagulation and fibrinolysis. A decrease in PAI-1 antigen concentrations and PAI-1
activity with metformin treatment  has been shown in many studies (154, 181, 182,
183, 373). A 24 - 48-month treatment with gliclazide has been shown to improve
fibrinolytic activity, increase tissue plasminogen activator (t-PA) concentrations,
and decreased PAI-1 activity (26). Gliclazide may also have an effect on fibrin
network structure, rendering it more amenable to fibrinolysis, and may exert a po-
tent free radical scavenging activity (237, 350). Inhibition of platelet adhesiveness
and aggregability has also been shown (257). A potentially beneficial effect on
prostacyclin/thromboxane ratios was also found (162).
Urinary albumin excretion
There are few data on effects of antihyperglycemic therapies on urinary albumin
excretion. These have been summarized in Tables 3 - 6.
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Serum insulin concentrations
Metformin generally decreases  serum insulin concentrations (113,154,182,373),
with a few exceptions, in two studies the insulin concentration did not change
(66,391). Sulphonylureas generally increase insulin (57,190,413). Glitazones im-
prove glucose tolerance, and decrease plasma insulin concentrations in a dose-
dependent manner (219,224,516,522). Acarbose decreases postprandial insulin
concentration compared with placebo or glibenclamide treatment (211). In the
UKPDS no significant effect on insulin sensitivity or β-cell function were seen with
acarbose treatment (216).
Markers of endothelial activation
Data are limited with respect to the effect of various oral antidiabetic agents on cir-
culating levels of adhesion molecules. Treatment with sulphonylurea, sulphonyl-
urea and metformin, and troglitazone for 2-3 months has been reported to decrease
sE-selectin concentrations, possibly because of reduced oxidative stress (96,97).
Gliclazide administration to type 2 diabetic patients may inhibit the increased adhe-
siveness of monocytes to endothelial cells and reduces the production of tumor ne-
crosis factor-α (TNF-α) by these cells (125,410).
Body weight
Metformin generally does not change or reduces body weight, while sulphonylureas
and especially glitazones increase weight. Acarbose does not greatly change body
weight while orlistat decreases it (Tables 3 - 6).
Hypoglycemia
Metformin does not cause hypoglycemia (113) while hypoglycamia is a problem of
sulphonylurea therapy. Glitazones or acarbose do not cause hypoglycemia
(216,413) (Table 2).
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2.2.4. Effect of oral agents on diabetic long-term complications
Macrovascular disease
So far there are limited data with respect to oral agents and macrovascular disease.
A detrimental effect of tolbutamide on CVD was reported in a study published in
1970 by the University Group Diabetes Program (UGDP) (1,260), which found that
CVD mortality was higher in patients given tolbutamide than in those given insulin
(12.7 % vs 6.2 %) (334). This study initiated the controversy of SU and cardiac
events. The UGDP results were widely debated and subsequently questioned be-
cause of a number of apparent problems with the study itself (107). In contrast,
Paasikivi found that treatment with tolbutamide, after an acute myocardial infarc-
tion was associated with decreased mortality  after 18 months compared with those
treated with insulin (369). In the Secondary Prevention Reinfarction Israel Nifed-
ipine Trial (SPRINT) (50), SU treatment after a cardiac infarction was associated
with lower mortality rates than was insulin treatment.
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By far the most extensive study examining effects of intensive therapy with either
sulphonylureas, insulin or metformin on macrovascular disease has been the
UKPDS. Intensive glycemic control, which was achieved using insulin or
sulphonylureas  (glibenclamide or chlorpropamide) decreased HbA1c by 0.9 % and
reduced macrovascular disease, as determined from the occurrence of myocardial
infarction, by 16 %, which was marginally significant (p=0.052) (Fig. 6).
Fig. 6. Adapted from UKPDS (14).  Kaplan-Meier plots of aggre-
gate endpoints: myocardial infarction for intensive and conven-
tional treatment
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Importantly, this risk reduction for MI: 14 % for a 1 % reduction in HbA1c (454)
corresponded closely to epidemiological predictions: 16 % lowering of MI for a 0.9
% decrease in HbA1c. This was perhaps the most important result of the UKPDS i.e.
that it proved insulin and sulphonylureas not to have any harmful effects on macro-
vascular disease, at least in newly-diagnosed patients who were relatively young
and free of coronary artery disease when the study started. In the UKPDS, in the
overweight subset of patients randomized to metformin, the incidence of myocar-
dial infarction decreased by 39 % compared with patients treated with diet alone or
insulin or sulphonylurea (13) (Fig. 7).
Fig. 7. Adapted from UKPDS (13) Kaplan-Meier plots of aggre-
gate endpoints: myocardial infarction for conventional (C), inten-
sive (I) and metformin (M) treatment. Metformin vs conventional
p < 0.01 and metformin vs intensive p < 0.12.
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Microvascular disease
In the UKPDS, intensive glucose control with either sulphonylurea or insulin sig-
nificantly (by 25 %) decreased the risk of microvascular complications (renal fail-
ure or death, photocoagulation, vitreous haemorrhage) (14,454) (Fig. 8).
Fig. 8. Adapted from UKPDS (14) Kaplan-Meier plots of aggre-
gate endpoints: microvascular disease, for intensive and conven-
tional treatment.
 In addition, there were significant decreases in cataract extraction (by 24 %), reti-
nopathy (by 21 %), and albuminuria (by 33 %) at twelve years (454).
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2.3 INSULIN TREATMENT IN TYPE 2 DIABETES
The major indication for insulin treatment in type 2 diabetes is chronic hypergly-
cemia which cannot be adequately controlled with OAD.
2.3.1. Effect of different insulin treatment regimens on risk factors and markers
of micro- and macrovascular complications and hypoglycemia
Effects of different combination therapies with insulin or insulin alone on various
risk factors and markers of complications have been included in Tables 7 and 8.
These tables include placebo controlled or parallel designed studies from 1990 and
have lasted at least 3 months. The tables are separated to insulin-naive patients and
previously insulin treated patients. Most of same kind studies before 1990 consisted
only 9 to 22 patients and lasted from 1 to 4 months (37, 187, 188, 255, 272, 293,
304, 365, 407, 414, 433, 452), two lasted one year and consisted 64 and 30 patients
respectively (70, 398) and one with 20 patients lasted 325 days (191).
Table 7. Effects of insulin containing regimens on various factors and markers of cardiovascular risk. Studies in insulin-
naive type 2 diabetes patients. Table includes studies, performed after 1990 and which have been either placebo con-
trolled or parallel designed and lasted at least 3 months
Study    n duration
of treat-
ment,
months
insulin concomitant
drug
HbA1c   or
change  %
FBG or
change
mmol/l
S-Tg S-Chol S-HDL S-LDL insulin dose
compared to the
other group
weight blood
pressure
Chow et al.
(83)
53 6 bedtime insulin
insulin b.i.d
SU and/or MET ↓ 1.5
↓ 2.2
↓ 4.9
↓ 3.7
↔
↓
↔
↔
↔
↔
               (15 IU)
↑ 380 % (57 IU)
↑
↑↑
Riddle et al.
(412)
21 4 premix 30/70 b.s.
premix 30/70 b.s.
glibenclamide
placebo
↓ 1.3
↓ 0.8
5.9
7.5
↓
↔
↔
↔
↔
↔
↔
↔ ↑ 58 %
↑↑
↑
Riddle et al.
(415)
145 6 premix 30/70 b.s.
premix 30/70 b.s.
glimepiride
placebo
7.6
7.7
7.6
7.6
↓
↓
↔
↔
↔
↑
↔
↔ ↑ 59 %
↑
↑
↔
↔
Wolffenbuttel et
al.
(519)
95 6 bedtime insulin
breakfast insulin
insulin b.i.d.
glibenclamide
glibenclamide
↓ 2.4
↓ 2.6
↓ 3.0
↓ 6.0
↓ 5.7
↓ 6.0
↓
↓
↓
↓
↓
↓
↑
↑
↑ ↑ 56 %
↑
↑
↑
Karlander et al.
(246)
20 11 premix b.i.d.
premix b.i.d.
glibenclamide
placebo
↓ 2.0
↓ 1.3
↔
↔
↔
↔
↔
↑
↓ 61 % ↑↑
↑
Landstedt-Hallin
et al.
(284)
80 4 preprandial regular
bedtime insulin
glibenclamide
glibenclamide
↓ 1.2
↓ 1.6
↓ 2.8
↓ 6.4
↓
↓
↓
↓
↔
↑ ↓ 10 %
↑↑
↑
n = number of patients,  b.s. = before supper, b.i.d. = insulin twice daily, SU = glibenclamide or glipizide or gliclazide, ↓ = significant
decrease or decrease in numbers, ↑ significant increase or increase in numbers, ↔ = not significant change
Table 8. Effects of insulin containing regimens on various factors and markers of cardiovascular risk. Studies in patients
treated previously with insulin. Table includes studies, performed after 1990 and which have been either placebo con-
trolled or parallel designed.
Study  n duration
of
treatment,
months
insulin concomitant
drug
HbA1c
or
change
%
FBG or
change
mmol/l
S-Tg S-Chol S-HDL S-LDL insulin dose
compared to the other
group
weight blood
pressure
Relimpio et al.
(409)
47 4 previous insulin
insulin increased
metformin ↓ 1.9
↓ 0.03
↓2.9
↓1.4
↓
↔
↓
↔
↔
↔
↓
↔ ↑ 20 %
↔
↔
↔
Aviles-Santa et al.
(36)
43 6 previous insulin
insulin    increased
metformin
placebo
↓ 2.5
↓ 1.6
↓3.5
↓3.5
↔
↔
↓
↓
↔
↔
↓
↓ ↑ 29 %
↔
↑
Feinglos et al.
(140)
37 3 previous insulin
insulin increased
glipizide
placebo
9.8*
11.4*
6.8
8.7
↔
↔
↓
↓
↔
↔
↓
↓ ↑ 21%
↔
↔
Kelley et al.
(250)
145 6 previous insulin
previous insulin
acarbose
placebo
↓ 0.7
↑ 0,1
↓ 2.8 ↓
↔
↔
↔
↔
↔
↑
↔
↔
↔
Robinson et al.
 study I (418)
19 3 previous insulin
previous insulin
metformin
placebo
↓ 1.1
↑ 0.5
↓ 3.8
↑ 1.9
↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
Robinson et al.
 study II (418)
14 3 previous insulin
previous insulin
metformin
replaced by
placebo
previous met-
formin re-
started
↑ 1.4
↓ 1.1
↑ 2.5
↓ 3.0
↔
↔
↔
↓
↔
↔
↔
↓
↑ 44 % ↔
↔
↔
↔
Lindström et al.
(299)
15 3 MDI
MDI
glibenclamid
placebo
6.0
6.3
7.0
7.8
↑
↔
↔
↔
↔
↔
↓
↔
↓ 25 % ↔
↔
Schwartz et al.
(437)
350 6 previous insulin
previous insulin
troglitazone
200 mg
600 mg
placebo
↓ 0.8
↓ 1.4
↓ 0.1
↓ 1.9
↓ 2.7
↔
↔
↔
↔
↑
↑
↔
↔
↑
↔
↑
↑
↔
↓ 11 %
↓ 29 %
↑
↑
↔
Giugliano et al.
(174)
50 6 previous insulin
previous insulin
metformin
placebo
↓ 1.8
↔
↓ 4.1
↔
↓
↔
↓
↔
↑
↔
↓ 25 % ↔
↔
↓
↔
Chiasson et al.
(82)
91 12 previous insulin
previous insulin
Acarbose
placebo
↓ 0.4
↓0.01
↑0.1
↑0.1
↔
↔
↔
↔
↔
↔
↔
↔
↓ 30 %
n = number of patients, * = HbA1,  MDI = multiple dose insulin, ↓ = significant decrease or decrease in numbers, ↑ significant increase or in-
crease in numbers,
 ↔ = not significant chan
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Glycemic control
According to a recent review (531), a total of 36 prospective comparisons (excludes
the FINMIS and FINFAT studies), each lasting 2 months or longer, between vari-
ous insulin-combination therapy regimens and insulin alone for the treatment of
type 2 diabetic patients have been performed. Of the 9 studies carried out in insulin-
naive patients, one compared insulin combined with sulphonylurea and metformin
to insulin alone (83) and 8 compared sulfonylurea and insulin to insulin alone (37,
44, 284, 398, 412, 414, 415, 519). Better glycemic control was achieved with com-
bination therapy in some studies (398,412,414) and similar improvement in others
(37,44,83,284,519). Reduction of the insulin dose averaged 60% when both
sulphonylurea and metformin were used in addition to insulin and 35% when
sulphonylurea alone was used.
In studies in previously insulin treated patients treated with insulin plus metformin
(36, 174, 409, 418), glycemic control was better compared with patients treated
with insulin only. In studies patients treated with insulin and sulphonylurea after
previous insulin therapy, glycemic control was better (191, 255, 272, 293, 301, 365,
407, 433, 452) or similar (70, 85, 140, 188, 299, 304) with insulin-combination
therapy than with insulin alone. In all studies comparing  insulin plus glitazones
with insulin alone, glycemic control was better with insulin-combination therapy
(402, 425, 437) than with insulin. In studies comparing insulin plus acarbose with
insulin alone, glycemic control has been either better (250) or similar (82) with the
combination than with insulin alone. Taken together this analysis shows that insulin
combination therapy has not resulted in worse glycemic control in any study hith-
erto published than treatment with insulin alone. Overall, in approximately half of
the studies insulin combination therapy has resulted in better glycemic control than
insulin alone.
Only two studies have been conducted to determine which patient characteristics
best predict a beneficial response to insulin or combined insulin and glibenclamide
therapy. Wolffenbuttel et al. (518) have shown that only duration of diabetes and
BMI were independent predictors of response to insulin. In their study poor re-
sponders were more obese and had significantly longer known duration of diabetes.
In the study of Lewitt et al. (293) patients were previously insulin treated and then
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glibenclamide was added to insulin therapy. Those who responded to that therapy
had higher C-peptide concentrations (p < 0.001) and shorter duration of insulin
therapy (p < 0.01) than those who did not responded.
Serum free fatty acids, lipids and lipoproteins
Elevations in FFA are associated with increased EGO and are reduced by small
doses of exogenous insulin (465). Acute increase in FFA induces insulin resistance
(144). Insulin treatment has shown to significantly decrease FFA levels in type 2
diabetic patients (284,412). One main effect of insulin on lipid metabolism in pe-
ripheral circulation is to stimulate lipoprotein lipase at the surface of endothelial
cells to hydrolyze triglyceride-rich lipoproteins. Taskinen et a.l (464) have shown
that intensive insulin treatment significantly reduces fasting FFA, total serum tri-
glyceride, VLDL triglyceride, total cholesterol phospholipids, LDL , apolipoprotein
B, and HDL3 subfractions, and increases the mass of the HDL2 subfraction, the ratio
of HDL2 to HDL3, apolipoprotein AI and adipose tissue lipoprotein lipase activity
(change +230 % in fat biopsies). Total HDL remained unchanged. These antiath-
erogenic lipid changes can only be achieved with very aggressive insulin therapy
but are in general consistent with other data (346).
In a double-blind study, where insulin and glibenclamide were compared, for com-
parative levels of glycemic control, insulin treatment was found to result in higher
HDL cholesterol and a higher HDL - total cholesterol ratio than glibenclamide
(351). Also in some cross-sectional studies SU treatment alone has been associated
with lower HDL cholesterol levels than insulin treatment (56,64,302). In contrast,
another study demonstrated that about 50 % of patients taking low-dose (< 40 U/d)
insulin experienced improved control of both blood glucose level and most of the
lipids except for HDL cholesterol when transferred from insulin to glipizide (421).
Yet in other studies the increase of HDL cholesterol was the same with insulin plus
placebo and insulin plus SU treatment (187,246,365).
There are only few long-term data on effects of various therapies on serum lipids in
type 2 diabetic patients. In the UGDPS, despite better glycemic control in the insu-
lin variable treatment group, the trends in changes in serum cholesterol and triglyc-
erides were not different from those observed in the placebo or insulin-standard
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treatment group (4). In an uncontrolled 5-year insulin treatment study with different
insulin treatment regimens there was a significant decrease of serum cholesterol
and triglycerides (267). In the Veterans Affairs Cooperative Study in Type 2 Dia-
betes, where the mean follow-up time was 27 months, there was no difference in
plasma lipids between the intensive and conventional insulin treatment groups (21).
Also, in one study using bedtime insulin and oral agents serum cholesterol concen-
tration decreased while those of triglycerides and HDL remained unchanged (430).
Blood pressure
When type 2 diabetic patients have been treated with an implantable insulin pump
(IIP) or with multiple doses of insulin (MDI) blood pressure has been reported to
decrease with IIP but not with MDI (432). In an uncontrolled five year follow-up
study of insulin treatment in type 2 diabetic patients, 68 % of patients had increased
blood pressure values at the start and 67 % at five year after onset of insulin therapy
(NS) (267). During the few studies, where treatment with insulin alone were com-
pared to insulin plus sulphonylurea, there was no change in blood pressure and no
difference within the groups (414,415). In one study, where insulin combination
therapy was compared with insulin glargine and NPH, blood pressure remained un-
changed for 1 year compared with baseline in both groups (534).
Coagulation and fibrinolysis
Studies concerning effects of insulin treatment on components of coagulation and
fibrinolysis are sparse. In three studies PAI-1 activity has slightly but significantly
decreased during insulin treatment (233,306,374). In two of these studies insulin
and sulphonylurea treatments were compared, with the latter treatment no change in
PAI-1 activity was found. In one study t-PA concentrations were higher when the
treatment consisted only of insulin (ultralente or soluble) or ultralente and
sulphonylurea than when only OAD were used (217). In contrast in one study no
change in PAI-1 and t-PA levels was found with insulin treatment (497).
Recently Melidonis et al. have demonstrated that PAI-1 and fibrinogen increase
remarkably in type 2 diabetic patients with acute myocardial infarction and that in-
tensive insulin therapy may prevent these increments (336).
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Urinary albumin excretion
Many studies including the study of Ohkubo et al. (361) and the UKPDS (14,15)
show that UAER decreases when glycemic control improves regardless of whether
insulin or SU is used to improve control. In the VA Study by Levin et al. (292) 153
male type 2 diabetic patients were randomly assigned to either intensive (HbA1c
goal 7.1 %) or standard (HbA1c goal 9.1 %) insulin treatment  and found that in in-
tensive insulin treatment group the progression of microalbuminuria was retarded
and the retardation was most pronounced in those patients who had microalbuminu-
ria at baseline.
Serum insulin concentrations
Serum free insulin concentrations increase significantly with all insulin treatment
regimens including those with evening NPH insulin (412,415), twice daily 30/70
regular/NPH insulin (300) with multiple insulin injections therapy (300,432) and
with implantable insulin pump therapy (432). Diurnal serum free insulin levels
have seldom been compared between two insulin regimens (412).
Markers of endothelial activation
Effect of insulin treatment on markers of endothelial dysfunction including circu-
lating adhesion molecules have only been investigated in two studies. In one study
16 patients with type 2 diabetes received 2 weeks of insulin treatment with continu-
ous subcutaneous insulin infusion (23). In this study, both sE-selectin and sVCAM-
1 concentrations decreased significantly. In the other study 22 poorly controlled
type 2 diabetic patients were treated for 16 weeks with insulin (542). HbA1c de-
creased from 11.8 % to 8.6 % but there were no significant changes in circulating
concentrations of vWF, cellular fibronectin, trombomodulin, t-PA, sE-selectin and
sVCAM-1. Serum C-reactive protein concentrations were, however, found to de-
crease significantly (542).
Body weight
Modest but significant weight gain commonly occurs with insulin treatment alone
(58,267,432) or in combination with SU (217,351,412,415,444,519,534) in type 2
diabetic patients. In three studies the weight gain was greater with insulin plus
sulphonylurea treatment than with insulin alone (246,284,412). In one study the
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weight gain was more pronounced when preprandial doses of regular insulin was
used with glibenclamide than when glibenclamide was used with bedtime dose of
NPH insulin (284). When Saudek et al. (432) compared IIP-therapy and MDI-
therapy in type 2 diabetic patients, there was no weight gain in IIP group while
weight continuously increased in the MDI group.
Hypoglycemia
It is not possible to prevent all hypoglycemic reactions with insulin treatment if the
goal is good glycemic control (71), but in those studies where hypoglycemic epi-
sodes have been reported, they have not been frequent and usually well tolerated. In
the UKPDS with  conventional insulin treatment, the rate of major hypoglycemic
episodes per year was 0.7 % and with the intensive insulin treatment 1.8 % (p <
0.0001). In one sulphonylurea and insulin combination treatment study the hypo-
glycemic episodes were significantly fewer in the evening insulin group than in the
morning insulin group (444) and in another study, where bedtime insulin glargine
was compared with bedtime insulin NPH during insulin combination therapy, there
were less overall and nocturnal hypoglycemia with insulin glargine (534). Regard-
ing severe hypoglycemia (requiring the assistance of another person), it can be es-
timated that the frequency is 19-fold higher in type 1 diabetes (31 episodes/100 pt
years, HbA1c 7.8 %) (8,401,404) than in type 2 diabetes (1.6 episodes/100 pt years,
HbA1c  8.0 %) (415,420).
Compared to type 1 diabetes (61 episodes/pt year, HbA1c 7.4 %) (278,401) the fre-
quency of mild hypoglycemia can be calculated to be 14-fold lower with type 2
diabetes (4 episodes/ pt year, HbA1c 8.0 %) (420).
2.3.2. Effect of insulin therapy on diabetic long-term complications
Macrovascular disease
The UKPDS tested whether intensive glucose control with insulin influences
macrovascular complications compared with conventional treatment (14). The inci-
dence of MI was reduced by 16 %, which was marginally significant (p = 0.052)
(Fig. 6) The predicted decrease, based on epidemiological data  from the same
study was 18 % for a 1 % reduction in HbA1c. The Diabetes Insulin-Glucose in
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Acute Myocardial Infarction (DIGAMI I) study (316,317) tested whether insulin-
glucose infusion initiated as soon as possible after the onset of MI and followed by
long-term subcutaneous insulin treatment may have beneficial effect on the progno-
sis of type 2 diabetic patients. In the insulin treated group there were 306 patients
and in the control group 314. The overall mortality after one year was 19 % in the
insulin group compared to 26 % among controls (p < 0.05). The treatment effect
was most pronounced in patients without prior insulin medication and who were at
a low cardiovascular risk. In this stratum the in-hospital mortality was reduced by
58 % (p < 0.05) and the one year mortality by 52 % (p < 0.02). The most frequent
cause of death in all patients was congestive heart failure (66 %), but cardiovascular
mortality tended to be decreased in insulin-treated patients. However, this differ-
ence did not reach the level of statistical significance.
In a recently published study (387) 2 years of intensive glycemic control with insu-
lin treatment did not affect the left ventricular systolic or diastolic function in pa-
tients with type 2 diabetes. Insulin therapy has been shown to normalize endothe-
lium-dependent vasodilatation, an early functional alteration in patients with type 2
diabetes (491).
Microvascular disease
In a 6 year prospective study Ohkubo et al. (361) showed that intensive glycemic
control by multiple insulin injection therapy can delay the onset and the progression
of diabetic retinopathy, nephropathy and neuropathy in Japanese patients with type
2 diabetes.
In the UKPDS (14) intensive insulin therapy decreased the risk of microvascular
end points in type 2 diabetes patients by 25 % (p < 0.01) (Fig. 8). The reduction in
microvascular risk was principally due to fewer cases of retinal photocoagulation
(29 % risk reduction, p < 0.005). There were also a decreased risk of deterioration
in retinopathy (21 % risk reduction at 12 years follow-up, p < 0.02) and microal-
buminuria (33 % risk reduction at 12 years follow-up, p < 0.0001). Importantly,
there was no threshold for the development of microvascular complications in the
UKPDS.
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2.3.3. Causes of weight gain during insulin therapy
Weight gain increases insulin resistance and thereby  naturally also increases its
consequences e.g. blood pressure (405).
Although most patients with type 2 diabetes are overweight, weight loss generally
precedes the diagnosis of type 2 diabetes (262). This weight loss is likely caused by
hyperglycemia- induced wasting of energy because glucosuria and excessive con-
sumption  are associated with glucose overproduction (60). When glucose control is
improved with insulin or sulphonylureas, energy loss in the urine decreases or
ceases, weight increases and basal metabolic rate (kJ/min) (157,503) and dietary
intake (313) are unchanged. The increase of body weight increases basal metabolic
rate, the decrease in glycemia decreases basal metabolic rate by decreasing the en-
ergy consumed for glucose overproduction. If dietary intake remains unchanged, as
has been observed (313), weight gain is proportional to reduction of glucosuria  and
its magnitude can be predicted from fasting glucose concentration (313). Because
glucosuria appears when the fasting glucose increases to 10 - 12 mmol/l, weight
gain is inevitable if insulin therapy is postponed until fasting glucose exceeds this
concentration. A 5 mmol/l decrease in fasting glucose or a decrease in HbA1c by 2.5
% from a baseline of 15mmol/l is associated with 5 kg of weight gain within 1 year,
or 2 kg for a 1 % decrease in HbA1c (313). The patient with poor glycemic control
before the start of insulin therapy but with a good treatment response is therefore at
greatest risk for weight gain. The possibility that metformin counteracts weight gain
when used in combination with insulin has not been studied.
2.3.4. Causes of variation in insulin requirements in type 2 diabetes
Theoretically, exogenous insulin requirements could depend on 1) β-cell function,
2) the amount of insulin absorbed, 3) the action of absorbed insulin on glucose me-
tabolism, 4) other factors such as insulin antibodies. Causes of variation in insulin
absorption have been sparsely studied in patients with type 2 diabetes. In one study,
subcutaneous fat thickness was not found to influence the disappearance rate of io-
dinated insulin (86). Insulin antibodies have not been found to influence insulin re-
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quirements (209). Whether inter-individual variation in insulin sensitivity modu-
lates insulin requirement in type 2 diabetes has not been studied.
One study with type 2 diabetic patients on continuous ambulatory peritoneal dialy-
sis has shown in multivariate analysis that duration of diabetes, HbA1c, and body
weight were independent determinants of insulin requirement in these patients
(520).
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3. AIMS OF THE STUDY
The present studies were conducted to answer the following questions:
1) What is the optimal insulin treatment regimen for type 2 diabetic patients (I, II)?
2) Do different bedtime insulin regimens differ with respect to their effects on weight
gain in type 2 diabetic patients (II)?
3) What are the causes of inter-individual variation in insulin requirements in type 2
diabetes (III)?
4) Does long-term improvement of glycemic control by insulin therapy decrease en-
dothelial activation as measured by serum levels of the soluble adhesion molecules
sE-selectin and serum vascular cell adhesion molecule sVCAM-1 (IV)?
4. SUBJECTS AND STUDY DESIGNS
Baseline characteristics of the subjects are presented in Table 9. The study  designs
are described below. All studies were approved by the local ethics committees.
Table 9. Characteristics of the study groups
Study I
Insulin treatment        Control group
group
Study II Study III Study IV
Type 2 diabetes     Normal
Patients                  subjects
Number of subjects 119 30 88 20 81 41
Men/Women 57/62 11/19 53/35 17/3 52/29 28/13
Age (y) 60±2 59±7 57±8 58±2 57±8 51±1*
Duration of diabetes
(y)
11±1 10±4 10±3 9±1 10±3 -
Body mass index
(kg/m2)
28.2±3.5 28.6±3.7 29±0.7 28.9±0.7 28.3±0.6 27.9±0.9
Fasting blood glucose
(mmol/l)
12.6±0.9 12.2±0.3 11.8±0.5 11.9±0.3 5.5±0.1
HbA1c ( %) 10±2 9.9±2 9.8±0.8 7.6±0.2 9.7±0.2 5.5±0.1
Serum triglycerides
(mmol/l)
2.40±0.2 2.2±0.2 2.5±0.3 2.1±0.2 2.5±0.1 1.1±0.05††
Serum total choles-
terol (mmol/l)
5.8±0.9 5.9±0.5 5.8±0.3 5.1±0.2 5.3±0.2 4.8±0.3*
Serum LDL-
cholesterol (mmol/l)
3.4±0.2 3.3±0.3 3.7±0.6 3.07±0.2 3.5±0.1 3.7±0.07
Serum HDL-
cholesterol (mmol/l)
1.4±0.2 1.4±0.2 1.1±0.5 1.1±0.4 1.1±0.4 1.3±0.3*
Data are shown as mean±SEM * p < 0.05 †† p < 0.0001 for type 2 diabetic patients versus normal subjects, y  = years
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4.1 Comparison of insulin regimens in type 2 diabetic patients (FINMIS-study) (I)
Design. 153 type 2 diabetic patients who were treated with  maximal doses of either glipizide
(15 mg per day) or glibenclamide (10.5 mg per day) alone or in combination with metformin
(0.5 to 2.0 g per day), a FBG concentration above 8.0 mmol/l and C-peptide concentration
above the lower limit of normal (0.33 nmol/l), were randomized to be treated with continued
OAD and NPH insulin in the evening (evening NPH group) or continued OAD and NPH in-
sulin in the morning (morning NPH group), a 2 insulin injection regimen NPH insulin and
regular insulin, in a ratio of 70 units to 30 units before breakfast and dinner (2 insulin injec-
tion group) without OAD, or a multiple insulin injection regimen, NPH insulin in the evening
and regular insulin given before breakfast, lunch and dinner (multiple insulin injection group)
without  OAD, or to continued OAD. Baseline clinical characteristics of the five groups are
shown in Table 10.
Table 10. Baseline clinical characteristics of the five groups of type 2 diabetic patients in study I (FINMIS)
Characteristic Morning-NPH
group
Evening-NPH
group
Two-injection
group
Multiple-
injection group
Control group
No. of patients 32 28 29 30 30
Men/women 12/20 15/13 12/17 18/12 11/19
Age (y) 59±8 60±6 59±7 60±5 59±7
Body-mass index (kg/m2) 27.6±3.6 27.9±3.2 28.7±4.0 28.8±3.2 28.6±3.7
Duration of diabetes (y.) 11±4 10±6 10±4 11±5 10±4
Fasting blood glucose (mmol/l) 12.5±2.4 12.2±2.4 12.4±2.4 12.5±2.8 12.2±2.1
Fasting serum C peptide (nmol/l)‡ 0.69±0.31 0.66±0.31 0.68±0.23 0.64±0.22 0.67±0.31
Serum creatinine (µmol/l)§ 80±9 80±9 80±9 80±9 80±9
Urinary albumin excretion (mg/24h)¶ 65±76 62±85 36±40 51±49 45±37
Oral hypoglycemic agents
  dose  (percent of group)
Glibenclamide (mg/day) 11±2 (81) 11±2 (89) 12±2 (81) 11±2 (88) 11±1 (89)
Glipizide (mg/day) 18±3 (17) 19±3 (14) 17±3 (18) 22±6 (10) 18±3 (10)
Metfrormin (g/day) 1.3±0.5 (59) 1.3±0.5 (64) 1.2±0.5 (55) 1.4±0.5 (60) 1.4±0.5 (57)
                                                                                                                                     percent of group
Beta-adrenergic-antagonists 27 25 35 36 44
Diuretics 28 21 23 12 33
Other drugs 68 61 54 64 65
* Plus-minus values are means ±SD
‡ Reference range, 0.33 to 0.69 nmol per liter
§  reference rang < 115 µmol /l
¶ Patients with rates of albumin excretion ≥ 300 mg per 24 hours were excluded.
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At the start of the study, the patients were admitted to hospital for 5 days. On day 1,
fasting blood glucose, HbA1c, serum lipoproteins, body weight and blood pressure
were measured. On day 2 insulin therapy was started and during the following days
adjusted to achieve normoglycemia, defined as a FBG < 7 mmol/l and PBG < 10
mmol/l. The patients visited the treatment center at  two weeks, one month and two
months after start of the treatment period. At these visits, results of the daily fasting
and weekly diurnal blood glucose measurements and hypoglycemia episodes were
reviewed, body weight and fasting blood glucose were measured and the insulin
dose was adjusted. After three months, patients were readmitted to hospital to re-
peat the tests performed on day 1.
4.2. Comparison of bedtime insulin regimens in type 2 diabetes (FINFAT-
study) (II)
.
Design. 96 type 2 diabetic patients, with a FBG above 8 mmol/l, C-peptide con-
centration above 0.33 nmol/l who were treated with maximal dose of either
glipizide (>15 mg per day) or glibenclamide (>10 mg per day), were recruited. Ex-
clusion criteria were congestive heart failure, myocardial infarction or stroke during
the past six months; epilepsy or other severe disease; liver disease; nephropathy as
determined by a serum creatinine concentration greater than 120 µmol/l or macro-
albuminuria; proliferative retinopathy or severe maculopathy; previous insulin ther-
apy for more than 2 weeks; excessive alcohol consumption; night work. The pa-
tients were randomized in four treatment groups: 1) bedtime NPH insulin and
glibenclamide (10.5 mg), 2) bedtime insulin and metformin (2 g), 3) bedtime NPH
insulin and glibenclamide (10.5 mg) and metformin (2 g), 4) bedtime NPH insulin
and morning NPH insulin.
Baseline clinical and biochemical characteristics of the different groups are shown
in Table 11.
Table 11. Baseline clinical and biochemical characteristics of type 2 diabetic patients in study II (FINFAT).
Characteristic Bedtime insulin
plus glibenclamide
group (n = 22)
Bedtime insulin plus
metformin group
(n = 19)
Bedtime insulin gliben-
clamide and metformin
group (n = 23)
Bedtime and morning
insulin group (n = 24)
Age, (y) 61±2 57±2 55±2 58±2
Men, (%) 59 58 61 67
Body mass index, (kg/m²) 29.7±1.0 28.9±1.1 29.5±0.9 28.5±1.1
Waist-to-hip ratio 0.93±0.02 0.93±0.02 0.95±0.02 0.94±0.02
Glycosylated hemoglobin value,
(%) †
9.8±0.3 9.8±0.4 9.9±0.3 10.1±0.4
Fasting blood glucose level,
(mmol/l)
11.7±0.5 12.3±0.5 11.5±0.6 12.1±0.5
Fasting serum C peptide level,
(nmol/l) §
1.1±0.1 1.1±0.2 1.0±0.1 1.1±0.1
Antihypertensive drugs, (%)
  Thiazides or ß-blockers 8 7 3 7
  Angiotensin-converting enzyme
inhibitors
9 10 9 7
Other drugs, (%) 50 42 40 42
Serum triglyceride level, (mmol/l) 2.7±0.5 2.4±0.4 2.3±0.2 2.6±0.5
Serum high-density lipoprotein
cholesterol level, (mmol/l) ||
1.1±0.1 1.2±0.1 1.1±0.1 1.2±0.1
Serum total cholesterol level,
(mmol/l)
5.7±0.2 5.9±0.3 5.8±0.2 5.8±0.3
Mean arterial blood pressure,
(mmHg)
106±2 105±2 108±2 103±3
Median urinary albumin excretion
rate (25th, 75th percentiles),
(µg/min)
26 (8, 37) 10 (9, 22) 10 (8, 31) 11 (7, 31)
* Unless otherwise specified, data are expressed as the mean ±SE. All data except lipid measurements were obtained 6 weeks before the start of therapy; lipid data were obtained at
the 0-month visit.
† Reference range, 4.0 % to 6.0 %.
§ Reference range, 0.33 to 0.75 nmol/l (1.0 to 2.0 ng/ml). To convert to ng/ml, divide by 0.333.
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Patients were taught to self adjust their insulin doses according to home glucose
measurements. The patients were given written instructions as shown in Table 12.
Table 12. Instructions to patients regarding self adjustment of bedtime insulin
doses
 FBG Insulin
dose ↑
Insulin
dose ↓
> 8.0 mmo/l on 3 consecutive days 4 IU/day
> 6.0 mmol/l on 3 consecutive days 2 IU/day
< 4.0 mmol/l on 3 consecutive days 2 IU/day
↑ = increase insulin dose, ↓ = decrease insulin dose, FBG = fasting blood glucose
Before start of insulin therapy, concentrations of FBG, HbA1c, fasting serum free
insulin, C-peptide, triglycerides, cholesterol, and HDL cholesterol, W/H and blood
pressure were measured. Following visits took place at 3 and 6 weeks and every 3
months for 1 year. At these visits, body weight, blood pressure, insulin dose, and
side effects were recorded and FBG was measured. HbA1c was measured every 3
months. Measurement of serum C-peptide and lipids and W/H were repeated at 12
months. Compliance was monitored through pill counting.
4.3. What are the causes of inter-individual variation in insulin requirements in
type 2 diabetic patients (III)
Design. Twenty type 2 diabetic patients with stable glucose control and insulin dose
for at least 6 months and on combination therapy with bedtime NPH insulin and
metformin for at least 1 year were admitted to the hospital 1 day before the studies.
The patients participated in the following studies: 1) measurement of action of in-
travenous insulin on endogenous glucose production and utilization (Fig. 9), 2)
measurement of absorption and action of subcutaneous insulin (Fig. 10) and 3)
measurement of liver fat content (proton spectroscopy) (Fig. 11), intra-abdominal
fat content (MRI) and subcutaneous fat thickness (ultrasound). In addition, body
weight and body composition were determined as described below.
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Fig. 9. Study design: measurement of  the action of intravenous
insulin on endogenous glucose production and utilization, using
euglycemic  insulin clamp technique combined with [3-3H]glucose
Fig. 10. Study design: measurement of insulin absorption, (in-
crease in free insulin and total insulin over 8 h after a subcutane-
ous dose (36 IU of regular insulin) and action of subcutaneous
insulin (glucose infusion rate required to maintain euglycemia
and suppression of FFA)
.
Glucose 20%
-5 0 2 4 6
Time (hours)
STUDY DESIGN / INSULIN SENSITIVITY
Insulin 0.3 mU/kg·min
3- 3H-glucose
Glucose 20%
0 2 4 6 8
Time (hours)
STUDY DESIGN / INSULIN ABSORPTION
subcutaneous injection of
36 IU regular insulin
glucose specific activity
serum insulin or free fatty acids
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Fig. 11. Proton magnetic resonance spectra from 2 patients with
fat percentages of 6  and 28 %. The water peak has a chemical
shift of 0 ppm, and the methylene (CH2) signal of fat has the
chemical shift of 3.4 ppm relative to the water peak. The height of
the signal (y-axis) is in arbitrary units.
4.4. Effect of long-term improvement in glycemic control on serum sE-selectin
and sVCAM-1 concentrations (IV)
Design. Subjects: 81 type 2 diabetic patients, who participated on study II (FIN-
FAT) and 41 normal subjects were studied. The type 2 diabetic patients were
treated with the following regimens: 1) bedtime NPH insulin and sulphonylurea (n
= 20), 2) bedtime NPH insulin and metformin (n = 17), 3) bedtime NPH insulin and
sulphonylurea and metformin (n = 21), 4) bedtime insulin and morning insulin (n =
23). The study design and measurements were as in study II. Serum sE-selectin and
sVCAM-1 concentrations were determined in extra serum samples taken at 0, 3 and
12 months.
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5. METHODS
5.1. Action of intravenous insulin (Study III)
At 8:00 p.m. on the evening before the study, an indwelling catheter, equipped with
an obturator, was placed in an antecubital vein. To determine total rates of glucose
production (Ra) - i.e. the sum of hepatic and renal glucose production (455) and
utilization (Rd) - a primed continuous intravenous infusion of [3-3H]glucose was
started at 3:00 a.m. and continued for total of 660 min. The priming dose of [3-
3H]glucose was adjusted according to the fasting blood glucose concentration
measured at 3:00 a.m., as follows: priming dose = [glucose  (mmol/l) at 3:00
a.m./5] x 20µCi. The dose was infused intravenously over 10 min. The continuous
rate infusion of [3-3H]glucose was thereafter stated at a rate of 0.2 µCi/min. At 7:30
a.m. another catheter was placed retrogradely in a heated (65 o C chamber) hand
vein to obtain arterialized venous blood (331). Baseline blood samples were taken
for measurements of insulin antibodies, total and HDL cholesterol, triglyceride and
C-peptide concentrations. At 8:00 a.m., after a 300-min equilibrium period a
primed continuous (0.3 mU . kg-1.  min -1) infusion of insulin was started, as previ-
ously described (123,395). Plasma glucose was allowed to decrease to 8 mmol/l
and was then maintained at this level for 360 min using a variable rate infusion of
20 % glucose based on plasma glucose measurements, which were made from arte-
rialized venous blood every 5 min. Blood samples for measurements of glucose
specific activity (SA) were taken at -30, -20, -10 and 0 min and at 15 to 30 min in-
tervals between 120 and 360 min. Serum free insulin concentrations were measured
every 60 min and serum FFA at 0, 10, 15, 20, 25 and 30 min and then at 30 to 60
min intervals during the insulin infusion.
[3-3H]glucose SA and calculation of glucose kinetics. Plasma was deproteinized
with Ba(OH)2  and ZnSO4 and evaporated as previously described (538). The dried
glucose residue was resuspended in water and counted in a double-channel liquid
scintillation counter (Reckbeta 1215; Wallac, Turku, Finland) after adding 10 ml
Aquasol liquid scintillation fluid (NEN-DuPont, Boston, MA) and corrected for
quenching. The [3-3H]glucose SA (in disintegrations per minute per micromole)
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was calculated by dividing  the disintegrations per minute in 0.3 ml plasma by the
plasma glucose concentration (in  micromoles per milliliter). The infusate was di-
luted 1:100 and 1:1000, and duplicates were counted to determine the infusate [3-
3H]glucose concentration. Glucose Ra and Rd were calculated using the Steele
equation, assuming a pool fraction of 0.65 for glucose and distribution volume of
200ml/kg for glucose (395). Endogenous glucose Ra was calculated by subtracting
the exogenous glucose infusion rate required to maintain euglycemia during hy-
perinsulinemia (0-360 min) from the rate of total glucose Ra. The percent suppres-
sion of basal endogenous glucose Ra during the final hour (300-360 min) by insulin
was used as an index of the sensitivity of endogenous glucose production to insulin
(percent suppression of endogenous Ra).
5.2. Absorption and action of subcutaneous insulin (Study III)
The patients did not take their bedtime NPH insulin injection before the insulin ab-
sorption study, which was performed after 10 to 12 h overnight fast starting at 7:30
- 8:00 a.m. Two indwelling catheters were inserted, one retrogradely in a heated
hand vein for withdrawal of arterialized venous blood and another for infusion of
20 % glucose. A fixed dose of 36 U regular insulin was injected subcutaneously by
the same investigator with a 29-gauge  needle 4 cm left of the umbilicus. The tem-
perature in the room was recorded in each study and was between 24 and 25 °C.
We chose a large insulin dose for two reasons. First, we wished to quantitate insulin
absorption from the increment in circulating free insulin concentrations, which can
only be done reliably if a relatively large dose is used. Second, we also wished to
quantitate the action of the subcutaneous insulin from the glucose infusion rate
needed to maintain glucose at its fasting concentration. We chose a fixed dose of
insulin and related the increment in circulating insulin concentrations to the esti-
mated distribution space of insulin. The latter is roughly equal to the extracellular
space and therefore closely correlated with fat-free mass (FFM) (537). A fixed
rather than a variable dose of insulin adjusted to body size was chosen, since the
absolute insulin dose injected influences the profile of absorbed insulin (285). Se-
rum free and total insulin concentrations were measured before and for 480 min
after the insulin injection, at 30 min intervals until 270 min and at 330, 420, and
480 min. Insulin absorption was calculated from the increase in free and total insu-
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lin concentrations above basal during the 480 min period and expressed as area
above basal divided by FFM (insulin absorption [mU/l] * min/kg FFM)
The action of subcutaneous insulin on glucose metabolism was assessed by deter-
mining the glucose infusion rate needed to maintain euglycemia during the 480 min
period. The glucose infusion rate was adjusted based on plasma glucose measure-
ments, which were performed from arterialized venous blood every 5 min for the
entire 480 min. The action of subcutaneous insulin on FFA metabolism was as-
sessed by measuring how serum FFA were suppressed  by the insulin injection. Se-
rum FFA were measured basally, at 10 min intervals between 0 and 60 min, at 30
min intervals between 60 and 270 min, and at 330, 420, and 480 min.
5.3. Measures of body composition (Study III)
Liver fat content measured by proton spectroscopy
Single-voxel (2x2x2 cm) proton spectra from the liver were acquired using 32 ex-
citations, a loop surface coil, and A 1.5 T magnetic resonance device (Magneton
Vision; Siemens, Erlangen, Germany). Spatial location was achieved using a
stimulated echo acquisition mode applied with a repetition time (TR) of 3000 ms
and an echo time (TE) of 20 ms. A long TR and short TE were chosen to minimize
effects of T1 and T2 relaxation, respectively, on signal intensities. Chemical shifts
were measured relative to water signal intensity (Swater) at 4.8 ppm. Methylene sig-
nal intensity (Sfat), which represents intracellular triglyceride in the liver (459) was
measured at 1.4 ppm. Signal intensities were obtained by time domain fitting rou-
tine VARPRO-MRUI (carbon.uab.es/mrui). This measurement of percent hepatic
fat by proton spectroscopy has been validated against the lipid content of liver bi-
opsies in humans (469) and animals (459). It has also been validated against liver
density measurements performed by computed tomography (305). The latter vali-
dation was repeated by quantifying liver density in 8 of the patients in the present
study with the HiQ computed tomography device (Siemens, Erlangen, Germany).
The entire liver was scanned with a 10-mm collimator. By using a standard region-
of-interest method, the density of normal liver parenchyma was calculated in
Hounsfield units. The percent liver fat measured by proton spectroscopy correlated
inversely (r = -0.85, p < 0.01) with liver density measured with computed tomogra-
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phy, so the measurements correlated closely with respect to the fatty liver. Hepatic
fat percentage was calculated by dividing (100 x Sfat) by the sum of Sfat and Swater.
(Fig. 11)
Abdominal fat distribution (MRI)
A series of T1-weighted transaxial scans for the determination of visceral and sub-
cutaneous fat were acquired from a region extending from 4 cm above to 4 cm be-
low the fourth and fifth lumbar interspace (6 slices, field of view  375 x 500 mm2,
slice thickness 10 mm, breath-hold TR/TE 138.9 ms/4.1 ms). Visceral and subcuta-
neous fat areas were measured using image analysis program Alice (Alice version
3.0 by Hayden Image Processing Group, Waltham, MA). A histogram of pixel in-
tensity in the intra-abdominal region was displayed, and the intensity corresponding
to the nadir between the lean and fat peaks was used as a cut point. Visceral adipose
tissue was defined as the areas of pixels in the intra-abdominal region above this cut
point. For correlation of subcutaneous adipose tissue area, a region of interest was
first manually drawn at the demarcation of subcutaneous adipose tissue and visceral
tissue. The measurement could not be performed in 3 subjects because of their large
body size.
Subcutaneous fat thickness (ultrasound)
The thickness, in millimeters, of the subcutaneous fat layer at the injection site was
determined by high-frequency  (10 MHz) ultrasound using an ImagePoint Mul-
tispacialty Ultrasound System (Hewlett Packard, Andover, MA)
Body weight and fat content
Body weight was recorded and fat free mass and percent body fat were determined
using a single frequency bioelectrical impedance analysis (BioElectrical Impedance
Analyzer System model #BIA-101A; RJA Systems, Detroit, MI) (156).
5.4. Cardiovascular risk predictors and markers (Studies I, II,III, IV)
Glycosylated hemoglobin (I, II, III, IV)
HbA1c was measured centrally in the same laboratory in all studies by high-
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performance liquid chromatography (453) using the fully automated Glycosylated
Hemoglobin Analyzer System (Bio-Rad, Richmond, CA).
Serum lipids and lipoproteins (I, II)
Total cholesterol, HDL cholesterol, triglycerides and lipoproteins were measured as
previously described (171,464).
Adhesion molecules (IV)
Serum sE-selectin (Parameter catalog no. BBE 2B; R&D Systems, Minneapolis,
MN) and sVCAM-1 (Parameter catalog no. BBE 3; R&D Systems) were measured
by solid-phase enzyme-linked immunoassays.
Serum free and total insulin concentrations (I, II, III)
Serum free insulin concentrations were determined after precipitation with polyeth-
ylene glycol (124) using the Phadesph insulin radioimmunoassay (RIA) kit (Phar-
macia, Uppsala, Sweden). Serum total insulin (IV) concentrations were measured
with the same RIA kit without the polyethylene glycol precipitation.
5.5. Other measurements (Study III)
Insulin antibodies
Insulin antibodies were determined after incubation of serum with [125 I]-insulin at
room temperature overnight by measuring total radioactivity and that remaining in
the supernatant after precipitation with polyethylene glycol (124,168).
5.6. Statistical analyses
(I) The distribution of data was analyzed and changes between the groups compared
with BMPD programs for detailed data description (program 2D) and analysis of
variance (program 7D), followed by the Bonferroni test. Changes within a group
were calculated by analysis of variance for repeated measures (program 2V).
Symptomatic hypoglycemias were analyzed by multiway tables (program 4F), fol-
lowed by Pearson’s chi-square statistic for comparison between groups. Linear re-
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gression analysis were performed by simple and multiple linear regression analysis
(program 8D and 1R).
(II) Analysis of variance for repeated measures was used for comparisons of normal
distributed variables between the groups. Post hoc pairwise comparisons between
the four groups were performed by using a Bonferroni correction if analysis of
variance for repeated measures had significant results. Kruskal-Wallis test was used
for comparison of means when the variance was not normally distributed. The
GraphPad Prism program (GraphPad Software, San Diego, CA) was used to fit data
relating indices of glycemia to frequency of biochemical hypoglycemias by
searching for the best fit among linear and various nonlinear regression models.
Goodness of fit was evaluated by the runs test and the F test (GraphPad Software).
Frequencies of hypoglycemia among the groups were compared by using the chi-
square test.
(III) Spearman’s nonparametric rank correlation coefficient was used for all corre-
lation analyses. Areas above basal were calculated using the trapezoid rule. Good-
ness of fit of individual nonlinear equations to mean data in the insulin absorption
test was analyzed using the runs test and R2 . Goodness of fit of different equations
was compared by calculating the significance of F ratio: whether, when using a
complicated versus simple model, the relative increase in sum of squares was
greater than the relative increase in degree of freedom. GraphPad Prism was used
for all calculations.
(IV) Normal distribution was tested using Kolmogorov-Smirnov nonparametric
test, and parameters non-normally distributed were log-transformed for statistical
analysis. Comparison between patients and controls were performed using the un-
paired Student’s t test. Data between treatment groups were compared using analy-
sis of variance for repeated measures, followed by post hoc pairwise comparison
using the Fisher’s least significant differences test. All correlation analyses were
calculated using Spearman’s rank correlation coefficient. GrapPad Prism (GraphPad
Software, San Diego, CA or Systat statistical package, SYSTAT, Evenston, IL)
were used for calculations.
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6. RESULTS
6.1. Comparison of insulin regimens in type 2 diabetic patients (FINMIS-study) (I).
Baseline clinical characteristics of the five groups of type 2 diabetic patients are
shown in Table 10.
Insulin dose
The mean (± SE) doses of NPH insulin in the two groups receiving an OAD and
NPH insulin were similar at three months (morning NPH group, 19 ± 1 U per day;
evening NPH group, 20 ± 2 U per day). The total doses of insulin were also compa-
rable in the two-injection group (total 43 ± 2 U per day; 27 ± 2 U per day before
breakfast, and 16 ± 1 U per day before dinner) and the multiple injection group
(total, 45 ± 3 U per day, regular insulin, 9.5 ± 0.7; 8.9 ± 0.7, and 9.4 ± 0.4 U per
day before breakfast, lunch, and dinner, respectively; and 17 ± 1 U of NPH insulin
per day at 9 p.m.)
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Serum free insulin concentrations (Fig. 12)
Fig. 12. Changes in the mean diurnal serum free insulin concen-
trations after 3 months in each insulin-treatment groups as com-
pared with the control group, as measured in the hospital. The
control group (+), the morning NPH group (o), the evening NPH
group (•) the two injection group (€), and  the multiple injection
group (). * p < 0.05 and † p < 0.01 for insulin treatment group
compared to with the control group. B = breakfast, L = lunch, D =
dinner.
At baseline, mean diurnal free insulin concentrations were comparable among the
groups and averaged 21 ± 1 mU/l. After 3 months of treatment, the mean diurnal
free insulin concentration had increased by 29 % in the morning NPH insulin
group, 14 % in the evening NPH insulin group, 39 % in the 2 injection group and
36 % in the multiple insulin group. When the insulin-treatment groups were com-
pared with each other, the increment in the evening NPH insulin group was signifi-
cantly less than in the other three groups (p < 0.05).
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Glycemic control
Glycemic control during the 6 week run-in period and during the treatment period
are shown in Fig. 13, 14 and 15 and Table 13.
Fig. 13. Glycemic control during the 6 week run in period and
during treatment in type 2 diabetic patients. The curves for mean
diurnal blood glucose concentrations represent 70 % of the re-
quested number of measurements in the five groups: the control
group (+), the morning NPH group (o), the evening NPH group
(•) the two injection group (€), and  the multiple injection group
(). During the run-in period, the mean value for glycosylated
hemoglobin decreased by 0.30 ± 0.09 percent (p < 0.001), the
mean diurnal blood glucose concentration by 0.89 ± 0.24 mmol/l)
(p < 0.001), and the mean FBG concentration by 1.7 ± 0.2 mmol/l
(p < 0.001). Each diurnal profile included blood glucose meas-
urements before and  1.5 hours after breakfast, lunch and dinner
and at 10 p.m. and 4 a.m.. The mean diurnal blood glucose con-
centration was significantly lower during treatment in each insu-
lin-treated group than in the control group p < 0.01 to p < 0.001.
p < 0.01 for the difference in values for glycosylated hemoglobin
between the insulin -treatment groups and the control group at
12 weeks.
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Fig. 14. Changes in mean diurnal blood glucose concentrations
after 3 months in each insulin-treatment group as compared with
the control group, as determined by home glucose monitoring.
* p < 0.05 and † p < 0.01. B = breakfast, L = lunch, D = dinner.
The control group (+). To convert values for glucose millimoles
per liter, multiply by 0.05551
Fig. 15. Changes in mean diurnal blood glucose concentrations
after 3 months in each insulin-treatment group as compared with
the control group, as measured in the hospital. * p < 0.05 and †p
< 0.01.    B = breakfast, L = lunch, D = dinner. The control group
(+). To convert values for glucose millimoles per liter, multiply by
0.05551
Table 13. Effect of insulin therapy on body weight, glycemic control, blood pressure, and serum lipid concentrations be-
fore and after three months of treatment in type 2 diabetic patient. (FINMIS)
Measure Morning NPH
group
Evening NPH group Two-injection
group
Multiple-injection
group
Control group
Baseline Change Base
line
Change Base
line
Change Base
line
Change Base
line
Change
Body weight (kg) 77.7±2.6 2.2±0.4
†‡
80.6±2.5 1.2±0.5
§¶
79.9±2.4 1.8±0.5
†‡
78.8±2.2 2.9±0.5
†‡
77.4±2.0 -0.9±0.4§
Glycosylated hemoglobin (%) 9.5±0.4 -1.7±0.3
†**
9.9±0.2 -1.9±0.2
†**
9.7±0.3 -1.8±0.3
†**
9.6±0.3 -1.6±0.3
†**
9.7±0.3 -0.5±0.2§
Mean diurnal serum free insulin
(µU/ml)
21±2 6±2
§**
20±2 3±2 23±3 9±2

22±2 8±2
§
23±3 -0.6±1.4
Blood pressure (mmHg)
Systolic
Diastolic
144±3
83±2
2±3
1±2
138±2
84±2
5±4
-1±2
139±3
82±2
-4±3
-2±2
143±3
84±2
2±3
-3±2
148±4
83±2
-10±4§
-7±3§
Serum triglycerides (mmol/l)
Total
VLDL
2.5±0.3
1.5±0.2
-0.3±0.2
-0.2±0.2
2.4±0.22
1.3±0.2
-0.6±0.2
††
0.3±0.1§
2.1±0.2
1.3±0.1
-0.4±0.1
§
-0.2±0.1
2.3±0.2
1.3±0.1
-0.6±0.1
‡‡
-0.4±0.1
‡
2.2±0.2
1.4±0.1
0±0.2
-0.1±0.1
Serum cholesterol (mmol/l)
Total
LDL
HDL
5.8±0.2
3.2±0.2
1.5±0.1
-0.2±0.3
0.1±0.1
-0±0.1
6.1±0.2
3.6±0.2
1.4±0.1
-0.4±0.1§
-0.1±0.1
-0±0
5.7±0.2
3.3±0.2
1.4±0.1
-0.4±0.2
-0.1±0.2
0±0.1
5.8±0.2
3.3±0.1
1.4±0.1
-0.2±0.1
0±0.1
0.1±0.1
5.9±0.2
3.3±0.1
1.4±0.1
0±0.1
0.1±0.1
-0.1±01
* To convert values for insulin picomoles per liter, multiply by 7.2
§P < 0.05 for the change from base line **P < 0.05 for the comparison with the changes in the control group
†P < 0.001 for the change from base line ‡P < 0.001 for the comparison with the changes in the control group
††P < 0.01 for the change from base line 	
	



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¶P < 0.05 for the changes between the evening-NPH group and the multiple-injection group
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The mean diurnal blood glucose concentration was significantly lower in each in-
sulin-treated group  than in the control group (p < 0.01 to p < 0.001). HbA1c values
decreased significantly and to similar extent in all the insulin-treated groups but
changed little in the control group. (Fig. 13).
The glycemic control improved equally well with all insulin-therapy regimens
though not to  ideal level.
Body weight (Table 13)
The patients in all insulin-treatment groups gained weight during the three-month
period. The smallest increment in body weight occurred in the evening NPH group
(mean 1.2 ± 0.5 kg) and the largest in the multiple-injection group (2.9 ± 0.5 kg),
p < 0.05 for comparison with the evening NPH group. The change in body weight
was inversely correlated with the change in glycosylated hemoglobin (r= -0.20,
p < 0.001) and positively correlated with the change in the mean diurnal serum free
insulin concentration (r = 0.23, p < 0.001), suggesting that weight gain occurred
concomitantly with improved glycemic control and hyperinsulinemia.
Hypoglycemia
The frequency of blood glucose concentrations below 4 mmol/l was 2 %, with no
significant differences between the insulin treatment groups.
Blood pressure (Table 13)
Blood pressure remained unchanged in all groups.
Lipids (Table 13)
The concentration of serum VLDL triglycerides decreased by 13 to 28 % in the in-
sulin treatment groups and by 7 % in the control group. The concentrations of total,
LDL, and HDL cholesterol remained unchanged.
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6.2. Comparison of bedtime insulin regimens in type 2 diabetes  (FINFAT-study)
(II)
Baseline clinical and biochemical characteristics of the different treatment groups
are shown in Table 11.
Insulin dose
After 12 months, the dosages of bedtime insulin were 24 ± 3 IU/d in patients re-
ceiving bedtime insulin and glibenclamide, 36 ± 9 IU/d in patients receiving bed-
time insulin and metformin (p < 0.01 compared with all other groups), 20 ± 3 IU/d
in patients receiving bedtime insulin and both oral drugs, and 24 ± 3 IU/d in pa-
tients receiving bedtime insulin and morning insulin. The dose of bedtime insulin
was significantly higher in patients receiving bedtime insulin and metformin than in
other patients at all time points starting 3 weeks after therapy (Fig. 16). In patients
receiving bedtime insulin and morning insulin the morning insulin dose averaged
16 ± 1 IU at 3 weeks and 29 ± 3 IU at 12 months.
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Fig. 16. Changes in body weight (top left), bedtime insulin doses
(bottom left), glycosylated hemoglobin value (top right) and
changes in the glycosylated hemoglobin value (bottom right)
during 12 months of insulin treatment in patients receiving bed-
time insulin and metformin (•), those receiving bedtime insulin
and glibenclamide ( ), those receiving bedtime insulin and both
oral agents (o), and those receiving bedtime insulin and morning
insulin (∆). In the top left and bottom left panels x = p < 0.05, xx =
p < 0.01, and xxx = p < 0.001 for bedtime insulin and metformin
compared with all other treatments, in top right and bottom right
panels x = p < 0.05 and xx = p < 0.01 for bedtime insulin and
metformin compared with bedtime and morning insulin and bed-
time insulin and glibenclamide, in the top right and bottom right
panels, * = p < 0.05 and ** = p < 0.01 for bedtime insulin and
glibenclamide and metformin compared with bedtime and morn-
ing insulin.
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Serum free insulin concentrations
Serum fasting free insulin concentrations were similar among the groups at baseline
and averaged 12 ± 1 mU/L. At 12 months, the mean fasting serum free insulin lev-
els were significantly increased (p < 0.05 for 12 months compared with 0 month),
they averaged 17 ± 2 mU/L in patients receiving bedtime insulin and gliben-
clamide, 22 ± 4 mU/L in patients receiving bedtime insulin and metformin, 16 ± 2
mU/L in patients receiving bedtime insulin and both oral drugs, and 19 ± 3 mU/L in
patients receiving bedtime and morning NPH insulin. Differences among groups
were not statistically significant.
Glycemic control
HbA1c concentrations were similar among groups before start of the treatment pe-
riod (Fig. 16). At 3 and 6 months after therapy, patients receiving bedtime insulin
and glibenclamide and metformin had a significantly lower HbA1c value than those
receiving bedtime insulin and glibenclamide and those receiving bedtime and
morning insulin (Fig. 16). This difference disappeared after 6 months (Fig. 16).
Unlike the other patients, patients receiving bedtime insulin and metformin showed
a progressive decrease in HbA1c values over time. At 12 months, HbA1c  values in
this group averaged 7.2 % ± 0.2 %; this change and the absolute change (-2.5 ± 0.4
percentage points) differed significantly from that in the other groups (Fig. 16). Di-
urnal glucose profiles showed that the greatest decreases occurred at 4 a.m. and be-
fore breakfast, whereas the smallest decreases occurred after dinner and at 10 p.m..
Glycemic control was significantly better in patients receiving bedtime insulin and
metformin than in the other groups during the last 3 months of the study (Fig. 16).
 Body weight
At 12 months, the patients receiving bedtime insulin and metformin had not gained
weight compared with 0 month, (mean change 0.9 ± 1.2 kg, Fig. 16). This was sig-
nificantly less than in the other groups, in which weight gain during 12 months
therapy averaged 3.9 ± 0.7 kg in patients receiving bedtime insulin and gliben-
clamide, 3.6 ± 0.8 kg in patients receiving bedtime insulin and both two oral drugs,
and 4.6 ± 1.0 kg in patients receiving bedtime and morning insulin.
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Hypoglycemia
During 12 months therapy, the mean number of symptomatic hypoglycemic epi-
sodes per patient was 3.4 ± 1.0 in the bedtime insulin and glibenclamide group, 1.8
± 0.4 in the bedtime insulin and metformin group, 3.3 ± 1.6 in the bedtime insulin
and both oral drugs group, and 3.9 ± 1.6 in the bedtime and morning insulin group.
The frequency of hypoglycemic episodes in patients receiving bedtime insulin and
metformin was significantly lower (p < 0.05) than that seen in patients receiving
bedtime and morning insulin. The mean frequency of biochemical (glucose level <
3.5 mmol/l)  hypoglycemic episodes in fasting blood glucose measurements was
significantly lower in the bedtime insulin and metformin group (1.1 %) and bedtime
and morning insulin group (1.2 %) than in the bedtime insulin and glibenclamide
group (2.2 %; p < 0.01 for comparison with both groups) and in the bedtime insulin
and glyburide and metformin group (1.8 %; p < 0.05). The frequency of biochemi-
cal hypoglycemic episodes was correlated with the mean blood glucose level in a
nonlinear fashion (Fig. 17).
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Fig. 17. Relation between the mean annual fasting blood glucose
concentration and the mean annual glycosylated hemoglobin
value (top) and the frequency of biochemical hypoglycemias
(bottom) (fasting glucose < 3.5 mmol/l). The regression equation
relating fasting glucose and glycosylated hemoglobin was as fol-
lows: glycosylated hemoglobin = 4.4 [95%  Cl, 3.3 to 5.5] +
0.50[Cl, 0.35 to 0.66] x fasting plasma glucose level [measured in
mmol/l]. The gray area in the top panel indicates the normal
range of glycosylated hemoglobin value. The dotted lines indi-
cate glycosylated hemoglobin values that correspond to fasting
glucose concentrations of 3 and 6 mmol/l.
The mean frequency of biochemical hypoglycemic episodes in the diurnal profiles
was 1 % during 12 months of insulin therapy. The frequency was significantly
lower among patients receiving bedtime insulin and metformin (0.6 %) than in
those receiving bedtime insulin plus glyburide (1.0 %; p < 0.05), those receiving
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bedtime insulin and both oral drugs (1.5 %; p < 0.001), and those receiving bedtime
and morning insulin (1.0 %; p < 0.05). The highest frequency of biochemical hypo-
glycemic episodes was at 4 a.m. in all groups (Fig. 18)
Fig. 18. Frequency (percentage of all measurements at a given
time point) of biochemical hypoglycemias (blood glucose con-
centration < 3.5 mmol/l) during home glucose monitoring  and di-
urnal glucose profiles. These frequencies differed significantly
among the groups before lunch (2.7 % of 648 measurements
before lunch in patients receiving bedtime insulin and gliben-
clamide and metformin compared with 0 % patients receiving
bedtime insulin and metformin [*** p < 0.001] and 0.1 % in pa-
tients receiving bedtime insulin and glibenclamide [*** p < 0.001])
and at 4 a.m. (4.7 % of 603 measurements at 4 a.m. in patients
receiving bedtime insulin and glibenclamide compared with 2.2 %
in patients receiving bedtime and morning insulin; * p < 0.05).
The frequency of hypoglycemia was also higher before lunch in
the bedtime insulin and morning insulin groups than in the bed-
time insulin and glibenclamide or metformin groups (** p < 0.01).
B = breakfast, L = lunch and D = dinner.
Blood pressure
Blood pressure remained unchanged in all groups during the treatment period (II).
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Lipids
Serum triglyceride concentrations were similar in all groups at baseline (Table 11).
During therapy, these concentrations decreased by 0.8 ± 0.3 mmol/l in the bedtime
insulin and glibenclamide group, 0.7 ± 0.3 mmol/l in the bedtime insulin and met-
formin group, 0.4 ± 0.2 mmol/l in the bedtime insulin and both oral drug groups,
and 0.9 ± 0.3 mmol/l in the bedtime and morning insulin group. P < 0.001 for
change compared with 0 months in all groups. Differences between the groups were
not significant. Serum total cholesterol and HDL cholesterol remained unchanged
in all groups during insulin therapy (II).
6.3. Causes of inter-individual variation in insulin requirements in type 2 diabe-
tes (III)
Variation in insulin absorption and action as   causes of variation in insulin re-
quirements
Absorption of subcutaneous insulin
The area above basal under the insulin absorption curve, measured as free or total
insulin, during the 480-min period was calculated for each patient to obtain an in-
dex of the amount of insulin absorbed. This index for free insulin, expressed as
milliunits per liter times minutes, was closely correlated to that expressed as milli-
units per liter times minutes per kilogram of body weight (r = 0.93, p < 0.0001) or
milliunits per liter times minutes per kilogram of FFM (r = 0.92, p < 0.0001). The
correlation between insulin absorbed, measured as the area under the total serum
insulin curve  (milliunits per liter times minutes) and that expressed as milliunits
per liter times minutes per kilogram body weight, was r = 0.95, p < 0.0001. The
correlation between the amount of insulin absorbed and that expressed as milliunits
per liter times minutes per kilogram of FFM was r = 0.95, p < 0.0001. The relation-
ships of parameters thought to influence insulin absorption are shown in Table 14.
The best correlates for both total and free insulin were visceral fat volume, subcuta-
neous fat volume, and BMI. The thickness of subcutaneous fat, varied between 1.6
and 3.8 cm, but was not significantly correlated with insulin absorption (Table 14).
Table 14. Relationships (Spearman’s) between measures of overall adiposity and body fat distribution and the amount of
absorbed insulin during the 480-min period in patients with type 2 diabetes.
Insulin area above basal (mU·l-¹·min-¹) Insulin area above basal (mU·l-¹·min-¹·kg-¹FFM)
Free Total Free Total
r P r P r P r P
Measures of overall adiposity
Visceral fat volume (ml) -0.73 0.0004 -0.55 0.015 -0.77 0.001 -0.55 0.014
Subcutaneous fat volume (ml) -0.60 0.0072 -0.57 0.010 -0.53 0.02 -0.59 0.0072
Subcutaneous fat (cm) -0.33 NS -0.29 NS -0.29 NS -0.30 NS
BMI (kg/m²) -0.59 0.006 -0.57 0.0085 -0.72 0.0004 -0.65 0.0018
Fat mass (kg) -0.41 NS -0.41 NS -0.46 0.04 -0.48 0.032
Body fat (%) -0.38 NS -0.44 0.05 -0.25 NS -0.43 NS
Weight (kg) -0.28 NS -0.24 NS -0.55 0.01 -0.40 NS
Measures of fat distribution
WHR -0.34 NS -0.25 NS -0.51 0.023 -0.24 NS
Visceral/subcutaneous fat
ratio
-0.22 NS -0.01 NS -0.33 NS -0.10 NS
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Action of the subcutaneous insulin
Fig. 19 depicts the mean ± SE for serum free and total insulin, plasma glucose, and
FFA concentrations and glucose infusion rate during 480-min period after subcuta-
neous insulin injection. The amount of free insulin absorbed, calculated as the area
above basal, area above basal divided by FFM and area above basal divided by
kilogram of body weight, varied 9.2, 10.6 and 10.9-fold.
Fig. 19. Absorption and action of subcutaneous insulin. Plasma
glucose concentrations (A), serum insulin concentrations (B),
glucose infusion rate (C), and serum FFA concentrations (D)
during 480-min period after subcutaneous injection of fixed dose
of regular insulin. Free insulin •, total insulin €, mean values,
dotted line patient with an exceptionally high bedtime insulin
dose (176 U).
The action of absorbed insulin was assessed by 2 parameters, suppression of serum
FFA (area under the FFA curve) and the amount of glucose infused to maintain
euglycemia between 0 and 480 min (M-value). The M-value varied 11.5-fold. The
ability of subcutaneous insulin to suppress FFA varied 7.5-fold. The amount of free
insulin absorbed  (area above basal over the 480 min period) was significantly cor-
related with both the area under the FFA curve during the 480-min period (r= -0.63,
p < 0.005) and M value (r = 0.74, p < 0.001) (Fig. 20). The corresponding correla-
tions for total insulin were r = -0.48, p < 0.05, and r = 0.62, p < 0.001 (Fig. 20).
96
Fig. 20. The relationship between the amount of free (upper
panels) and total (lower panels) insulin absorbed after subcuta-
neous injection (area above basal) and the action of subcutane-
ous insulin on FFA (A) and M-values (B).
Action of intravenous insulin
The time course for plasma glucose, serum free insulin, and FFA concentrations
and the glucose infusion rate for the intravenous insulin action study are shown in
Fig. 21.
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Fig. 21.  Plasma glucose (A), serum free insulin (B), glucose in-
fusion rate (C), and FFA (D) during the euglycemic insulin clamp
study. Data are means ± SE.
Plasma glucose concentrations were similar in all subjects between 240 and 360
min and averaged 8.2 ± 0.2 mmol/l. The M-value (0-360min) varied 10.8-fold.
During the final 2 h, glucose Rd averaged 2.75 ± 0.20 mg .  Kg-1 . min-1 and endoge-
nous Ra 1.17 ± 0.23 mg kg-1 . min-1, which represented a 67 ± 7 % suppression be-
low basal. FFA averaged 759 ± 53µmol/l basally and decreased to 352 ± 38 µmol/l
between 240 and 360 min. Action of intravenous insulin to suppress FFA (area un-
der the FFA concentration curve between 0 and 360 min) varied by 4.6-fold.
Relationships between the sensitivity of endogenous Ra to insulin during the final
hour of intravenous insulin infusion and measures of overall  adiposity and fat dis-
tribution in type 2 diabetic patients are shown in Table 15. The % hepatic fat was
the best correlate of the %  suppression of  EGO by insulin (Fig. 22).
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Table 15. Relationship (Spearman’s) between measures of overall adi-
posity and body fat distribution and the sensitivity of endogenous Ra to
insulin in patients with type 2 diabetes
Percent suppression 300-360 min
        Range                  Fold variation                   r                             P
Liver fat (%) 2 – 28 14.0 0.72 0.0013
Measures of overall
adiposity
  Visceral fat volume
(ml)
179 – 2053 11.5 0.56 0.0297
  Subcutaneous fat
  volume (ml)
526 – 1765 3.4 0.67 0.0065
  Subcutaneous fat (cm) 1.6 – 3.8 2.3 0.32 NS
  BMI (kg/m²) 23.3 – 36.4 1.6 0.54 0.026
  Fat mass (kg) 15 – 39 2.6 0.60 0.01
  Body fat (%) 22 – 39 1.8 0.51 0.037
  Body weight (kg) 67 – 127 1.9 0.44 NS
Measures of fat
distribution
  WHR 0.92 – 1.17 1.3 0.58 0.01
Viceral/subcutaneous
fat ratio
0.34 – 1.37 4.0 -0.02 NS
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Fig. 22. The relationship between fat mass and percent liver fat
(C) and between percent liver fat and suppression of EGO by in-
travenous insulin (A), between percent liver fat and insulin dose
(U/day [B] and U * kg -1 *day-1 [D]).
Insulin antibodies
The titer of insulin antibodies averaged 9.8 ± 1.6 % (range 3.6 - 27.3 %). The cor-
relation between the titer of insulin antibodies and the daily insulin dose did not
reach statistical significance (r = 0.37, p = 0.11)
Relationship between  insulin absorption and action, insulin antibodies, and the
daily insulin dose
The amount of insulin absorbed, measured either as free (r = 0.38, NS) or total in-
sulin (r = 0.27, NS) during any 30-min time period between 0 and 480 min did not
correlate significantly with the insulin dose, whereas the ability of subcutaneous in-
sulin to suppress FFA (r = 0.70, p < 0.001) and M-value (r = -0.61, p < 0.005) were
significantly correlated with the daily insulin dose (Fig. 23).
100
The relationship between the action of intravenous insulin to suppress serum FFA
(r = 0.46, p < 0.05, FFA area under curve at 0 - 360 min) and M-value (r = -0.46, p
< 0.05, 0 - 360 min) and the daily insulin dose were significant, albeit weaker than
the relationship between the action of subcutaneous insulin and insulin dose (Fig.
23)
Fig. 23.  The relationship between actions of intravenous (i.v.) (A
and C) and subcutaneous (s.c.) (B and D) insulin on glucose in-
fusion rate (A and B) and antilipolysis ( C and D) and insulin
dose. GINF = glucose infusion rate.
To examine the combined effects of insulin absorption, action and antibodies on
daily insulin requirements, multiple linear regression analysis was used. The great-
est F ratio (13.4, p < 0.001 for model) and R2 (61.3%) were found when the daily
insulin dose (units per day) was the dependent variable and the action of subcuta-
neous insulin to suppress FFA (p < 0.001) and insulin antibodies (p = 0.05) were
the independent variables. The F ratio was 10.2 (p < 0.002 for model), and R2 was
54.7 % when the actions of intravenous insulin to suppress FFA (p < 0.002) and in-
sulin antibodies (p = 0.05) were included as the dependent variables. Inclusion of
the amount of absorbed insulin, measured as either free or total insulin, did not im-
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prove the model. Use of M-value or intravenous insulin action on Rd or endogenous
Ra instead of insulin suppression of FFA as a measure of insulin action did not im-
prove the model.
Hepatic fat content and its relationship to measures of total adiposity and fat dis-
tribution
The % fat in the liver varied 14-fold, from 2 to 28 %. Relationships with the % liver
fat and measures of total adiposity and fat distribution were calculated with Spear-
man´s rank correlation coefficients. In univariate analyses, several measures of adi-
posity (BMI, r = 0.63, p = 0.006; % body fat r = 0.60, p = 0.011; subcutaneous fat
volume, r = 0.62, p = 0.016) but especially total fat mass were significantly corre-
lated with % of liver fat (Fig. 22), but neither W/H (r = 0.40, NS) nor the ratio be-
tween visceral and subcutaneous fat volume (r = 0.02, NS) was correlated with the
% of liver fat.
Hepatic fat role in insulin requirement in type 2 diabetes
Table 16 and Fig. 22 show the relationships (Spearman´s r) between measurements
of overall adiposity and fat distribution and the daily insulin dose. The % hepatic
fat was the parameter best correlated with the insulin dose.
Table 16. Relationship (Spearman's) between measures of overall adi-
posity and body fat distribution and the daily insulin dose expressed as
units per day and units per kilogram per day in patients with type 2 dia-
betes
Insulin dose (U/day)
    r                P
Insulin dose (U·kg-1·day-1)
          r                     P
Liver fat (%) 0.76 0.0004 0.77 0.0003
Measures of overall
 adiposity
  Visceral fat volume (ml) 0.46 0.0048 0.42 0.07
  Subcutaneous fat volume (ml) 0.47 0.0041 0.50 0.03
  Subcutaneous fat (cm) 0.04 NS 0.03 NS
  BMI (kg/m²) 0.68 0.0009 0.61 0.004
  Fat mass (kg) 0.60 0.005 0.58 0.007
  Body fat (%) 0.31 NS 0.37 0.11
  Body weight (kg) 0.63 0.003 0.50 0.02
Measures of fat distribution
  WHR 0.69 0.0008 0.61 0.004
Visceral/subcutaneous fat ratio 0.01 NS -0.05 NS
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 6.4. Does improvement of glycemic control  by long term insulin therapy affect
endothelial activation measured by sE-selectin and sVACAM-1(IV)
The characteristics of the type 2 diabetic patients and control subjects are shown in
Table 17, and the metabolic parameters  in patients with type 2 diabetes grouped
according to the treatment regimens in Table 18.
Table 17.  Characteristics of the study groups. Study IV
0 months
Patients with type 2 diabetes (n = 81)
3 months 12 months
Normal subjects
(n = 41)
Age (y) 58 ± 1 51 ± 1 **
Sex (M / F) 52 / 29 28 / 13
Weight (kg) 82.4 ± 1.7 83.8 ± 1.7 § 86.0 ± 1.8 §# 81.8 ± 1.8
Fat-free mass (kg) 56.5 ± 1.3 58.4 ± 1.7 60.9 ± 1.8 §# 58.2 ± 0.9
Waist-to-hip ratio 0.94 ± 0.01 0.94 ± 0.01 0.95 ± 0.01 ‡|| 0.91 ± 0.01
HbA1c(%) * 9.7 ± 0.2 8.1 ± 0.1 § 7.6 ± 0.1 §# 5.5 ± 0.1 ††
Fasting plasma glucose (mmol/l) 11.9 ± 0.3 6.8 ± 0.3 § 6.3 ± 0.1 § 5.5 ± 0.1 ††
Serum triglyceride level (mmol/l) 2.5 ± 0.1 1.6 ± 0.1 § 1.9 ± 0.2 §|| 1.2 ± 0.05 ††
Serum HDL cholesterol level (mmol/l) 1.1 ± 0.4 1.2 ± 0.04 † 1.1 ± 0.04 ¶ 1.3 ± 0.03 **
Serum LDL cholesterol level (mmol/l) 3.5 ± 0.1 3.4 ± 0.1 3.4 ± 0.1 3.7 ± 0.07
Data are n or means ±SEM. * Reference range 4.0 - 6.0%. †P < 0.05, ‡P < 0.01, §P < 0.001 for 3 or 12 vs. 0
months; ||P < 0.05, ¶P0.01,
#P < 0.001 for 12 vs. 3 months, **P < 0.05, ‡P < 0.001 for patients with type 2 diabetes versus normal
subjects, †† p < 0.0001.
Table 18.  Metabolic parameters in the patients with type 2 diabetes
grouped according to the treatment regimen
BI+SU BI+MET BI+SU+MET BI+MI
Sex (F/M) 7/13 8/9 8/13 6/17
Age (y) 61 ± 2 57 ± 2 56 ± 2 59 ± 2
BMI (kg/m²), 0 months 28.7 ± 0.8 27.8 ± 0.9 28.6 ± 0.7 28.0 ± 1.1
Change in weight (kg),12-0 months 3.6 ± 0.7 * 2.1 ± 1.0 *§ 3.7 ± 0.9 * 4.6 ± 1.1 *
HbA1c (%), 0 months 9.4 ± 0.3 9.9 ± 0.4 9.8 ± 0.4 9.8 ± 0.4
Change in HbA1c (%), 12-0 months -1.8 ± 0.3 -2.6 ± 0.4 -2.1 ± 0.3 -1.9 ± 0.4
Serum triglyceride level (mmol/l), 0 months 2.7 ± 0.6 2.3 ± 0.4 2.4 ± 0.2 2.7 ± 0.5
Change in serum triglyceride level (mmol/), 12-0
months
0.3 ± 0.1 0.5 ± 0.5 0.1 ± 0.1 0.1 ± 0.3
Serum sE-selectin level (ng/ml), 0 months 72 ± 7 94 ± 11 66 ± 7 80 ± 7
Serum sE-selectin level (ng/ml), 3 months 65 ± 7 † 77 ± 11 * 60 ± 6 * 68 ± 5 ‡
Serum sE-selectin level (ng/ml), 12 months 67 ± 8 * 78 ± 10 † 62 ± 6 75 ± 7 *
Serum sVCAM-1 level (ng/ml), 0 months 363 (318-55) 362 (272-508) 356 (244-401) 448 (280-596)
Serum sVCAM-1 level (ng/ml), 3 months 334 (259-399) * 335 (236-429) † 312 (227-355) * 447 (288-593)
Serum sVCAM-1 level (ng/ml), 12 months 353 (309-439) 347 (308-509) 315 (227-487) 453 (317-593)
Data are n, means ±SEM, and median (range). *P < 0.05, †P < 0.01, ‡P < 0.001 for 3 or 12 vs. 0 months; §P <o.o5
versus other groups. BI=bedtime insulin, MI=morning insulin
Serum sE-selectin was 71 % higher in the type 2 diabetic patients than in the nor-
mal subjects at baseline. This difference remained essentially unchanged after ad-
justment for serum triglyceride and HDL cholesterol concentrations, blood pres-
sure, BMI, W/H, and age and also for CHD. Sixteen type 2 diabetic patients had
CHD. In the type 2 diabetic patients there was no gender difference in sE-selectin
concentrations, whereas the sE-selectin concentration was 64 % higher in normal
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men than women. Serum sVCAM-1 concentrations were comparable between the
type 2 diabetic patients and the normal subjects (Table 18).
Effect of insulin therapy in glucose control, body weight and serum lipids
During 1 year of insulin therapy, HbA1c decreased from 9.7 ± 0.2 to 7.6 ± 0.1 % (p
< 0.001) and fasting blood glucose from 11.9 ± 0.3 to 6.3 ± 0.1 mmol/l (p < 0.001).
Body weight increased by 3.6 ± 0.5 kg (p < 0.001). Serum triglycerides decreased
by 24 % from 2.5 ± 0.1 to 1.9 ± 0.2 mmol/l (p < 0.001). Serum LDL cholesterol
concentrations remained unchanged and were comparable to those of the normal
subjects (Table 18)
Effect of insulin therapy in serum sE-selectin and sVCAM-1 concentrations
After 3 and 12 months insulin therapy serum sE-selectin concentrations had de-
creased significantly compared to 0 months (Fig. 24), but the concentration at 12
months was still 55 % higher than in the normal subjects (Fig. 24). Serum sVCAM-
1 decreased transiently during the first 3 months and then increased back to base-
line (Table 18) by 12 months.
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Fig. 24. Glycosylated haemoglobin and serum sE-selectin con-
centrations before and after 3 and 12 months of treatment of 81
patients with type 2 diabetes with various bedtime insulin regi-
mens and 41 normal subjects. +++ p < 0.001 vs. patients with type
2 diabetes at 0, 3, 12 months. *** p < 0.001 for 3 and 12 vs. 0
months.
Correlations between clinical and biochemical characteristics and serum sE-
selectin and sVCAM-1 concentrations
At baseline, HbA1c correlated with sE-selectin concentrations in diabetic men (r =
0.29, p < 0.05), but not in diabetic women (r = -0.07, NS). None of the other clini-
cal or biochemical parameters correlated with sE-selectin at baseline. Within the
normal subjects, the % of body fat correlated with sE-selectin both in men (r =
0.48, p < 0.01) and women (r = 0.63, p < 0.05). Serum triglycerides were also posi-
tively correlated with sE-selectin concentrations both in women (r = 0.65, p < 0.05)
and in men (r = 0.38, p < 0.05).
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The change in HbA1c, by 1 year of insulin therapy both in diabetic men and women,
was significantly correlated with the change in sE-selectin concentrations (Fig. 25).
Changes in other parameters did not correlate with the change in serum sE-selectin
concentrations.
 sVCAM -1 concentrations correlated with HbA1c at baseline both in diabetic
women (r = 0.47, p < 0001) and men (r = 0.28, p < 0.05). In the control subjects,
the % fat (r = 0.56, p < 0.005) in women and systolic blood pressure in men (r =
0.38, p < 0.05) were significantly correlated with sVCAM-1 concentrations.
Fig. 25. Relationship between change in glycemic control versus
serum sE-selectin concentrations within the patients with type 2
diabetes. • BI+SU,  BI + MET ,▼BI + SU + MET, ▲ BI + MI.
BI=bedtime insulin; MI=morning insulin
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7. DISCUSSION
7.1 Comparison of insulin treatment regimens in patients with type 2 diabetes
Type 2 diabetes is regarded as a progressive disorder (13, 14, 114), where use of in-
sulin is frequently necessary at some stage of the natural course of this disease.
When these studies were begun more than 10 years ago, data comparing effects of
various insulin regimens on glycemic control and other cardiovascular risk markers
were sparse (191, 238, 382, 394, 398). Insulin treatment was frequently started in a
hospital following the principles used to treat patients with type 1 diabetes. These
principles often included prescription of a diet which included snacks in addition to
main meals and use of multiple insulin injections. We decided to question this ap-
proach given that type 1 and 2 diabetes are fundamentally different diseases. From
the point of view of insulin therapy, it is important to remember that 80 % of pa-
tients with type 2 diabetes are obese (169) when insulin therapy is started and that
weight gain is a frequent and undesirable side effect. Because of obesity and possi-
bly other factors, type 2 diabetic patients are also markedly insulin resistant even
when normoglycemic, in contrast to type 1 diabetic patients, who are normally sen-
sitive to insulin if normoglycemic (535, 536). On the other hand, there are type 2
diabetic patients who are lean and not necessarily insulin resistant. These consid-
erations suggest that patients with type 2 diabetes need greater insulin doses than
patients with type 1 diabetes and also that variation in insulin requirements is much
greater than in patients with type 1 diabetes. Another factor which could have im-
plications with respect to insulin therapy is the presence of  residual endogenous in-
sulin secretion in type 2 diabetic patients. It might be possible to use simple insulin
regimens perhaps together with one or two oral agents, which allow satisfactory
glycemic control to be achieved without the use of  multiple insulin injections and
frequent blood glucose monitoring. Possibly use of agents such as metformin might
counteract weight gain or use of insulin at bedtime rather than in the morning. The
timing of the insulin injection might simply influence eating patterns and possibly
be beneficial in counteracting weight gain.
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Glycemic control, weight gain and insulin requirements during various insulin
treatment regimens
To test the validity of the above hypotheses, 2 major studies comparing insulin
treatment regimens were performed. In the first study called FINMIS, 153 poorly
controlled type 2 diabetic patients were treated with four different insulin regimens
or with continued maximal doses of two oral agents. In this study (I), we found, for
the first time, that use of evening NPH insulin combined with oral drugs improved
glycemic control as much as other insulin regimens including the regimen where
multiple insulin injections was used but was associated with less weight gain than
the other regimens. This beneficial effect on body weight has subsequently been
confirmed in many studies (85, 412, 415, 430). Clearly, the beneficial effect on
body weight of the evening NPH and sulfonylurea and metformin combination
regimen was not due to metformin, since the group using identical oral drugs but
NPH in the morning gained more weight than the group injecting insulin in the
evening. However, the study did raise the question of whether a similar result could
have been obtained by using only one agent and if so whether this agent then
should be a sulfonylurea or metformin. The FINFAT study (II) was designed to an-
swer this question. In this study 4 different bedtime insulin regimens were com-
pared for 1 year in 96 patients with type 2 diabetes. The patients were previously
treated with sulfonylurea only to maximize the likelihood of observing differences
in weight gain which could be attributable to use of metformin. Results of this
study were striking in the sense that the group using bedtime NPH and metformin
differed from the other groups in several respects. This group experienced the least
weight gain, had the best glycemic control and also the lowest number of hypogly-
cemia. The latter also explained why this group was able to increase their insulin
dose more than the group using bedtime NPH and sulfonylurea. From data avail-
able in the literature, one could calculate that on the average use of a maximal dose
of either a sulfonylurea or metformin reduces insulin requirements by 32 % and use
of two agents by 62 % (531). In the FINFAT study, the insulin dose in the 2-
injection group was 53 IU/day, in the bedtime NPH and glibenclamide group 24
IU/day, in the bedtime NPH and metformin group 36 IU/day, in the bedtime NPH
plus glibenclamide and metformin 20 IU/day. Thus, the insulin dose was 32 %
lower in the bedtime insulin and metformin and 62 % lower in the group using
bedtime NPH and 2 oral agents than in the 2-injection group. The unexpected find-
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ing was that the group using NPH and glibenclamide used only 24 IU/day i.e. 55 %
instead of the expected 30 % less than the 2-injection group. This finding was,
however, explained by greater frequency of hypoglycemia in this as compared to
the other groups. Of note, these results may not be generally applicable to all inter-
mediate or long acting insulins and not necessarily to all sulfonylureas. For exam-
ple, insulin glargine, which has a peakless time-action profile compared to NPH
(290) may not induce as much hypoglycemia with a sulfonylurea than NPH (534).
In our experience the combination of metformin and bedtime insulin can be used
both in obese and lean type 2 diabetic patients. The obese patients may have even
greater benefit than lean, because of the ability of metformin to counteract weight
gain. In another study (539),  we have shown that after an initial good response,
glycemic control deteriorates more in obese than in non-obese patients with insulin
alone or with insulin and sulphonylurea plus metformin. In that study, after one
year of treatment, HbA1c was not significantly lower than that at the baseline, but in
the FINFAT study - after one year of treatment with metformin and bedtime insu-
lin, glycemic control was still good.
Lipids and blood pressure during insulin therapy
In both studies I and II, serum lipids and lipoproteins changed rather similarly re-
gardless of the insulin treatment regimen. Serum triglycerides decreased by 12 to
25 % in 3 months with the insulin regimens in study I and by 17 to 35 % in 12
months with the regimens in study II. Serum total, HDL and LDL cholesterol re-
mained unchanged in all studies. The lack of change in HDL cholesterol can be ex-
pected as insulin therapy increases LPL activity and the mass of HDL2 particles but
decreases that of HDL3 (464). These data indicate that from the point of view of
lipids and lipoproteins, use of a simple combination therapy regimen is not disad-
vantageous compared to more complicated regimens.
In study I systolic and diastolic blood pressures decreased significantly in the con-
trol group but remained unchanged in all insulin-treatment groups. In study II blood
pressure also remained unchanged in all treatment groups. It is important to note
that neither study was powered to detect changes in blood pressure. The decrease in
blood pressure in the control group but not in the insulin treatment groups in study I
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could be due to changes in body weight i.e. body weight decreased in the control
group and increased in all insulin treatment groups. In a follow-up of the FINMIS
patients, a highly significant increase in systolic blood pressure was observed (539).
In the latter analysis, the increase in blood pressure was significantly correlated
with changes in body weight and an increase in LDL cholesterol.
Serum  insulin concentrations
In study I during the 3 months of treatment, the mean diurnal free insulin concen-
tration increased by 29 % in the morning-NPH group, 14 % in the evening-NPH
group, 39 % in the two injection group and 36 % in the multiple-injection group as
compared with the values at baseline.  The increment in the bedtime NPH and sul-
fonylurea and metformin group was significantly smaller than in the other groups.
This suggests, in the face of similar improvement in glycemic control that either
nocturnal insulinization is more effective in lowering glucose concentrations than
daytime increments in insulin concentrations, or that endogenous insulin can act
better during the day to suppress EGO during meals during bedtime NPH combina-
tion than during morning NPH or multiple insulin injection therapy.
Body weight
Modest but significant weight gain commonly occurs with insulin treatment alone
(58, 267)   or combination with sulphonylureas (217, 351, 412, 415, 444, 519, 534)
in type 2 diabetic patients. In study I improvement in glycemic control was signifi-
cantly correlated with weight gain in the insulin treatment groups, whereas the op-
posite was true in the control group. As discussed above, the weight gain in the in-
sulin treated patients is likely to be caused by inhibition of hyperglycemia- induced
wasting of energy because of glucosuria and excessive energy consumption  associ-
ated with glucose overproduction (60). If dietary intake remains unchanged, as we
have previously observed during treatment with insulin alone as well as with insu-
lin plus metformin (313), weight gain is proportional to reduction of glucosuria and
can even be predicted based on how much the fasting glucose concentration de-
creases (313).
Factors other than correction of glycemia also influence weight gain. In study I, the
patients in the evening-NPH group gained less weight than the patients treated with
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other insulin regimens. The cause of this phenomenon remains speculative. One
possibility is that insulin itself promotes weight gain. Since serum free insulin in-
creased less in the evening-NPH than in the other groups, peripheral hyperinsuli-
nemia may perhaps have been responsible for weight gain via stimulation of lipo-
genesis in adipose tissue and  stimulation of appetite (62).
The data from study II demonstrate that metformin prevents weight gain during in-
sulin therapy. This beneficial effect of metformin is consistent with previous data
from studies comparing oral agents such as the Multicenter Metformin Study (118)
and more recently the UKPDS (16). The mechanisms underlying the beneficial ef-
fect of metformin on body weight is unclear. Recent data of causes of weight gain
in patients using insulin alone and those using insulin and metformin suggests,
however, that the weight gain-sparing effect of metformin is due to reduced energy
intake (313).
Hypoglycemia
The frequency of biochemical hypoglycemia in study I (blood glucose < 4 mmol/l)
was 2 % of all measurements, with no significant differences between the insulin
treatment groups and there were no serious hypoglycemia episodes. When com-
pared to e.g. the DCCT (12) study, the frequency of biochemical hypoglycemia in
the present study was close to that of severe hypoglycemia in the DCCT implying
that hypoglycemia is much less common in type 2 than in type 1 diabetes. In study
II the frequency of symptomatic and biochemical (blood glucose < 3.5 mmol/l) hy-
poglycemic episodes was approximately 2-fold lower in patients receiving bedtime
insulin plus metformin than in the other groups (Fig.18). These data are consistent
with those of the UKPDS (11), in which the frequency of any hypoglycemia in pa-
tients using metformin was 4-fold lower than in patients with equally well-
controlled type 2 diabetes who received glibenclamide. Data from studies I and II
suggest that metformin combined with glibenclamide does not reduce hypoglyce-
mic episodes i.e. that use of glibenclamide masks any beneficial effect of metfor-
min on hypoglycemia.
As in patients with type I diabetes (9), the frequency of hypoglycemic episodes was
closely correlated with mean fasting glycemia. Although no severe hypoglycemic
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episodes occurred, the frequency of biochemical hypoglycemic episodes increased
markedly when the mean annual fasting glucose level was less than 6 mmol/l (Fig.
17). The latter glucose level corresponded to a mean annual HbA1c value of 7.4 %
(Fig. 17). These data imply that normoglycemia is not necessarily a safe target
during insulin therapy and that it is not realistic to achieve normoglycemia by using
bedtime insulin combined with metformin, glibenclamide or a second injection of
insulin.
Self adjustment of insulin dose – a key to successful insulin therapy
In the FINMIS and FINFAT studies the range of the insulin requirements varied at
least 20-fold i.e. from 8 to 168 IU/day (I-II). The causes of this large variation are
unknown but were explored in study III. Even after the knowledge accumulated in
study III, it is, however, impossible to exactly predict insulin requirements in an in-
dividual patient, which means that the insulin dose has to be titrated individually. If
a patient needs 168 IU of bedtime insulin, and treatment is started with a low dose
such as 10 IU/day, and the dose is adjusted only at outpatient visit every 3 months
by 4 units, it would take 119 months or approximately 10 years before the treatment
goal would be achieved. In the FINFAT study, the 168 IU dose was achieved in 6
months because the patient was taught self-adjustment of the insulin dose. This ex-
treme example illustrates how important it is to develop flexible and simple algo-
rithms which can be used by the patient, to achieve glycemic targets in a reasonable
time frame. It is also noteworthy that in the FINFAT study, insulin therapy was not,
as in study I started in the hospital but on an outpatient basis.
7.2. Causes of variation in the insulin dose (III)
Study III was undertaken to determine causes of variation in the insulin dose of pa-
tients with type 2 diabetes, who were in relatively good glycemic control with a
stable insulin dose. Theoretically, insulin requirements could depend on the amount
of insulin absorbed, the action of absorbed insulin and possibly other factors such
as insulin antibodies. Previous insulin absorption studies have been performed al-
most exclusively in patients with type I diabetes using iodinated insulin ([125I]-
labeled regular insulin) to trace insulin absorption (109, 161, 209, 264, 285, 496).
Those studies have shown that insulin absorption, at constant temperature under
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resting conditions, is slowed by increases in subcutaneous fat thickness (208, 441),
total dose injected (285), decreases in subcutaneous blood flow (207, 495, 496) and
injection site (208). Insulin antibodies have not been found to influence insulin re-
quirements (209), nor has the amount of insulin absorbed been shown to correlate
with insulin action in normal subjects (544). Causes of variation in insulin absorp-
tion have been sparsely studied in patients with type 2 diabetes. In one study, sub-
cutaneous fat thickness was not found to influence the disappearance rate of iodi-
nated insulin (86). Whether interindividual variation in insulin sensitivity modu-
lates insulin requirements in type 2 diabetes has not been studied. For those rea-
sons, we wished in study III to quantify the extent to which insulin absorption and
action determine insulin requirements in patients with type 2 diabetes. On separate
days, using [3-3H]glucose and the euglycemic insulin clamp technique, we deter-
mined the amount of absorbed insulin from the increment in free and total insulin
concentrations after a subcutaneous injection of regular insulin and the action of
intravenous insulin on suppression of FFA and glucose production and utilization.
The action of subcutaneous insulin was also quantitated by measuring the ability of
subcutaneous insulin to suppress FFA. To search for causes of variation in insulin
absorption and action, several parameters characterizing body size, fat content, and
fat distribution were quantitated. These parameters included measurements of he-
patic fat content by proton spectroscopy, visceral fat by MRI, body fat content by
bioimpedance plethysmography, and subcutaneous fat thickness by ultrasound.
Insulin absorption
The  mean insulin dose of the patients using bedtime NPH insulin and metformin
was 42 IU/day (36 IU/day excluding the patient using 176 IU/day). To mimic the
mean dose, to enable ranking of patients with respect to their insulin sensitivity, and
to make the absorption study feasible to perform, 36 IU of regular insulin was in-
jected subcutaneously, and the increase in free and total insulin concentrations and
glucose requirements for the ensuing 8-h period were followed. This period was not
long enough to allow the entire absorption and action profile to be determined (Fig.
19). The amount of absorbed insulin therefore only provides an index of insulin ab-
sorption. Even in normal subjects, absorption of regular insulin is markedly slow.
In the study by Ziel et al. (544), the maximal concentration of regular insulin in
non-diabetic non-obese subjects after a 10 IU subcutaneous injection was observed
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at 112 min, and the glucose infusion rate was maximal at 256 min. Even after sub-
cutaneous injection of a short-acting insulin analog (21 IU to non-obese non-
diabetic subjects), the glucose infusion rate remains increased until 8 h (204). Con-
sistent with these observations, the possibly slower insulin absorption in obese type
2 diabetic patients than in type 1 diabetic patients (86) and the decrease in the rate
of insulin absorption at increasing insulin doses, the glucose infusion rate did not
reach maximum until ~360 min after the subcutaneous injection in the present study
(Fig. 19). Although the insulin concentrations, the action of subcutaneous insulin
on serum FFA concentrations, and the glucose infusion rate did not return to the
baseline within the 8-h period, the absorption study nevertheless provided some
useful information about absorption and action of the subcutaneous insulin. First,
the significant correlation between the amount of absorbed insulin and its action on
both FFA and glucose metabolism (Fig. 20) suggests that variation in insulin ab-
sorption had biologically significant consequences. Second, the significant correla-
tion between the action of absorbed insulin and the insulin dose on one hand (Fig.
23) and the better correlation between subcutaneous than intravenous insulin action
and the insulin dose on the other, support the idea that measurement of insulin ab-
sorption provided physiologically meaningful information, and that the amount of
absorbed insulin does influence insulin requirements because it influences insulin
action.
Insulin action
In searching for factors associated with insulin requirements, the correlation be-
tween the ability of insulin to suppress serum FFA and the insulin dose was better
than that between the M-value and the insulin dose (Fig. 23). Also the correlation
between actions of subcutaneous and intravenous insulin was clearly better for ac-
tion on FFA than on glucose metabolism. The superiority of FFA suppression ver-
sus the M-values as a measure of insulin action is likely to be technical because the
glucose concentrations were variable during the insulin absorption study. Such
variations in the glucose concentrations will induce some variation in M-values be-
cause of the mass action effect of hyperglycemia (540). Because antilipolysis is not
regulated by glucose in humans (532), use of the area under the FFA curve during
insulin infusion or injection is subject to less variability than M-value under condi-
tions of varying glycemia. Insulin action seemed a more important determinant of
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variation in insulin requirements than insulin absorption since there was no correla-
tion between the amount of insulin absorbed and insulin dose, but there was highly
significant correlation between subcutaneous insulin action and the insulin dose.
Measures of obesity
Regarding causes of variation in insulin absorption several measures of body fat
(visceral and subcutaneous fat volume, BMI, weight, and fat mass) rather than sub-
cutaneous thickness at the injection site were found to be associated with the
amount of insulin absorbed, regardless of whether the area under the absorption
curve or the area divided by FFM was used as the measure of the amount of insulin
absorbed. Previous data in type 2 diabetic patients are sparse. In the study of Clau-
son et al. (86) in type 2 diabetic patients, insulin absorption was followed using of 5
U regular [125I]-insulin. In that study, which included obese and non-obese patients,
no correlation was observed between depth of the fat layer and residual radioactiv-
ity at the 3 injection sites examined (86). On the other hand, consistent with the
present data, studies performed  in type 1 diabetic patients have demonstrated sig-
nificantly slower insulin absorption, measured as residual radioactivity at the injec-
tion site, in obese than in non-obese patients (441, 495). As in the present study,
however, subcutaneous fat thickness did not explain variation in insulin require-
ments in these studies (441, 495).
Of the simple parameters measured, BMI was one that correlated with the amount
of absorbed insulin (Table 14), the percent fat in the liver, the sensitivity of EGO
(Table 15), and insulin dose (Table 16). Thus insulin is more slowly absorbed and
acts less efficiently to suppress EGO and FFA concentrations in obese than in non-
obese patients. These factors increase not only the absolute insulin dose but also the
dose needed per kilogram of body weight.
Hepatic fat content
Because inhibition of EGO represents the major target for insulin therapy (338,
465), it was particularly interesting to search for parameters that might explain in-
ter-individual variation in hepatic insulin sensitivity. Percent liver fat was found to
be most closely correlated with suppression of EGO by insulin (Table 15). It was
also correlated with the insulin dose. The results suggests that 60 % of the variation
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in daily insulin dose (Fig. 22) was attributable to variation in hepatic fat content,
possibly via effects of hepatic adiposity on the sensitivity of EGO to insulin (Fig.
22). This relationship may seem surprisingly strong considering that daily insulin
requirement should also be influenced  by inter-individual differences in diet com-
position and exercise habits. When body weight is stable and physical activity hab-
its are constant, however, insulin requirements also should stabilize. Because
physical activity and body weight are key determinants of insulin sensitivity (529),
and inhibition of EGO is the primary target of insulin therapy (528), the correla-
tions between liver fat content, insulin sensitivity, and insulin requirements are
physiologically feasible and expected.
The relationship between liver fat percentage and hepatic insulin sensitivity sup-
ports recent evidence that has led to the classification of nonalcoholic steatohepati-
tis (NASH) as a disease of affluence and part of the insulin resistance syndrome
(234). In the Third National Health and Nutrition Examination Survey, 2.6 % of the
U.S. population had raised values of serum alanine aminotransferase (ALT) for
which no potential cause of chronic liver disease could be found (234). The raised
ALT concentration was significantly and independently associated with indexes of
insulin resistance and with HbA1c concentrations. The risk of steatosis increases
exponentially with each addition of a component of the insulin resistance syn-
drome, such as IGT, BMI, hypertension, and dyslipidemia (322). Patients in this
study had normal transaminases, but percent liver fat varied 14-fold, from 2 to 28
%, suggesting that noninvasive measurement of liver fat content is a more sensitive
index of steatosis than elevation of ALT, although the diagnosis of NASH still rests
on histopatological features (234). The mechanisms linking insulin resistance and
fatty liver are unclear. It has been suggested, but not confirmed, because of the in-
accessibility of the portal vein for blood sampling in humans, that fatty liver is a
consequence of fatty acid mobilization from visceral fat depots to the liver (31). In
the present study, visceral fat volume, WHR, and the visceral/subcutaneous fat  ra-
tio were not significantly correlated with percent liver fat, whereas measures of
overweight (total and subcutaneous fat mass, percent body fat, and BMI) were. No
causal conclusions can be made based on these correlation analyses. They do not
exclude the possibility that hyperinsulinemia, which could result from obesity-
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induced primary insulin resistance in skeletal muscles (296) and from exogenous
insulin injections, itself might increase hepatic fat content (318).
7.3. Effect of insulin therapy on markers of endothelial activation
CVD is the major complication of type 2 diabetes (273). Endothelial activation and
dysfunction are amongst the first steps in its evolution (393). In study IV sE-
selectin and sVCAM-1 concentrations were determined in 81 patients with type 2
diabetes before and after 3 and 12 months of treatment with four different bedtime
insulin regimens. Improvement in glycemic control was associated with a signifi-
cant decrease in serum sE-selectin concentrations. The decrease was highly signifi-
cantly correlated with improvement in glycemic control and was not dependent on
the pharmacological agent used to improve glycemia. In contrast to sE-selectin,
sVCAM-1 exhibited a transient decrease at 3 months and was not significantly dif-
ferent from concentrations in normal subjects at any time point.
In previous cross-sectional studies, sE-selectin levels have been an average 43 %
higher in patients with type 2 diabetes than in normal subjects (23, 42, 97, 125, 128,
271), also in type 2 diabetic patients without CHD (42, 128, 271, 367). In study IV
the increase in the type 2 diabetic patients before insulin therapy averaged 71 % and
there was no gender difference in type 2 diabetic patients as there is in normal sub-
jects (42). In contrast to sE-selectin, sVCAM-1 concentrations did not differ be-
tween patients with type 2 diabetes and normal subjects in this study. This negative
finding is in keeping with lack of a difference in sVCAM-1 concentrations between
type 2 diabetic patients and normal subjects in half of the previous studies (23, 24,
108, 125, 242, 297, 451), and a small mean 12 % difference in sVCAM-1 concen-
trations between type 2 diabetic patients and normal subjects, when all studies are
analyzed together (23, 24, 42, 95, 97, 108, 125, 128, 242, 297, 451).
Although hyperglycemia in vitro stimulates the production of both E-selectin,
VCAM-1 and ICAM-1 (341), this study demonstrating a sustained decrease in sE-
selectin but not in sVCAM-1 supports the idea that in vivo sE-selectin is a sensitive
marker of hyperglycemia induced endothelial activation, and these data support the
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potential usefulness of sE-selectin as compared with sVCAM-1 to monitor reversal
of early vascular dysfunction by antihyperglycemic therapies.
Regarding the mechanisms linking hyperglycemia and sE-selectin concentrations, it
seems possible that glucose-induced increased oxidative stress is involved (325,
341). Glycosylated hemoglobin concentrations are associated with reduced plasma
antioxidant trapping capacity in patients with type 2 diabetes (312), a finding con-
sistent with the concept that clinically relevant hyperglycemia increases oxidative
stress. However antioxidant treatment (N-acetyl-L-cysteine) has decreased
sVCAM-1 levels in one study (108), although it has not been possible to decrease
sE-selectin or sVCAM-1 levels by tomato juice (478), α-tocopherol (478) or gli-
clazide (125). Because treatment of hyperglycemia has reduced sE-selectin levels in
three studies (23, 94, 95) and in the present study, it could be considered a better
tool than antioxidants to lower sE-selectin concentrations in type 2 diabetes. Such
lowering might be important because sE-selectin concentrations have been shown
to predict restenosis in patients with intermittent claudication undergoing percuta-
neous transluminal  angioplasty (51) and levels of soluble forms correlate with en-
dothelial expression (384). On the other hand, no data presently exist regarding the
predictive value of sE-selectin concentrations for future vascular events in patients
with type 2 diabetes, and no data exist to demonstrate that lowering of sE-selectin
reflects a beneficial change in vascular function.
        7.4.  Choice of  the insulin treatment regimen
In type 2 diabetes there are abnormalities in insulin secretion and insulin action, so it
is reasonable to treat them both. If the hypothesis of progressively deteriorating β-
cell function in type 2 diabets (286) is correct, insulin therapy will ultimately be re-
quired by all of type 2 diabetic patients if the patient lives long enough.
We have shown that similar metabolic control can be achieved with different simple
combination treatment regimens as with multiple insulin injections (FINMIS and
FINFAT). In addition the FINFAT study showed that treatment with bedtime insulin
and metformin gives best glycemic control and is associated with less hypoglycemia
and weight gain than other bedtime insulin regimens.
118
Many factors influence the choice of insulin treatment regimen, such as the patients’
psychosocial background, lifestyle, propensity for hypoglycemia, age, obesity and
ability of the patient to self-administer insulin. Thus, there is no universally applica-
ble regimen. It is therefore important to carefully examine these factors in each indi-
vidual patient before recommending an insulin treatment regimen, also including the
patients motivation.
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SUMMARY AND CONCLUSIONS
I    In poorly controlled type 2 diabetic patients receiving oral hypoglycemic drug
therapy, the addition of NPH insulin in the evening improves glycemic control in a
similar manner as a two-insulin-injection therapy regimen and multiple-insulin-
therapy regimen, but induces less weight gain and hyperinsulinemia.
II   Combination therapy with bedtime insulin plus metformin prevents weight gain
and seems superior to other bedtime insulin regimens with respect to improvement
in glycemic control and frequency of hypoglycemia.
III   S.c. insulin absorption is a determinant of the action of s.c. insulin but not of
the insulin dose. Actions of s.c. and i.v. insulin to suppress FFA are significantly
correlated. The actions of i.v. insulin and s.c. insulin are both correlated with the in-
sulin dose. Of various measurements of adiposity, the % hepatic fat is the parameter
best correlated with hepatic sensitivity to insulin and insulin dose.
These data demonstrate that the major reason for inter-individual variation in insu-
lin requirements in type 2 diabetes is the variation in insulin action. Variation in
hepatic fat content may influence insulin requirements via an effect on the sensitiv-
ity of EGO to insulin.
IV  Improvement in glycemic control by administration of insulin alone or insulin
combined with either glibenclamide, metformin, or both agents induces a sustained
decrease in sE-selectin, the magnitude of which seems to be dependent on the de-
gree of improvement in glycemia. sE-selectin might provide a marker of effects of
treatment of chronic hyperglycemia on endothelial activation.
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